University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Doctoral Dissertations

Graduate School

5-2013

Contribution of microRNAs and Robo4 signaling after herpes
simplex virus infection: Role for regulatory mechanisms
Sachin Vishvas Mulik
smulik@utk.edu

Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss
Part of the Immunology and Infectious Disease Commons

Recommended Citation
Mulik, Sachin Vishvas, "Contribution of microRNAs and Robo4 signaling after herpes simplex virus
infection: Role for regulatory mechanisms. " PhD diss., University of Tennessee, 2013.
https://trace.tennessee.edu/utk_graddiss/1764

This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee
Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized
administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact
trace@utk.edu.

To the Graduate Council:
I am submitting herewith a dissertation written by Sachin Vishvas Mulik entitled "Contribution of
microRNAs and Robo4 signaling after herpes simplex virus infection: Role for regulatory
mechanisms." I have examined the final electronic copy of this dissertation for form and content
and recommend that it be accepted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy, with a major in Comparative and Experimental Medicine.
Barry T Rouse, Major Professor
We have read this dissertation and recommend its acceptance:
Timothy Sparer, Stephen Kennel, Seung Baek
Accepted for the Council:
Carolyn R. Hodges
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)

Contribution of microRNAs and Robo4 signaling after
herpes simplex virus infection: Role for regulatory
mechanisms

A Dissertation presented for the
Doctor of Philosophy Degree
The University of Tennessee, Knoxville

Sachin Vishvas Mulik
May 2013

Dedicated to my advisor, Barry Rouse

"

!!"

Acknowledgements
“You are one, they are many. If you don't work hard night and day, they will crush you
like a roach" (Günter Blobel)
I express my sincere thanks towards my advisor Dr. Barry T Rouse for his
penetrative insights, enthusiastic support, constructive criticism and steadfast
encouragement throughout the course of my research. I am extremely grateful to other
members of my advisory committee, Dr. Timothy Sparer, Dr. Seung Baek and Dr.
Stephen Kennel for their valuable suggestions and insights. I also thank Dr. David Brian,
Dr. McEntee and Dr. Nathan Schmidt for their unfailing help, support and guidance.
Words fail to express my gratitude towards my loving lab members Pradeep,
Naveen, Tamara, Fernanda, Sid and Leon for their affection, kindness, encouragement
and their care and interest in my educational and personal matters. I wish to extend whole
hearted thanks to my friends Amol, Aman, Pranay, Sathish, Sujata, Nancy, Kim and
Misty for their understanding, support, pleasurable company and timely help in crisis.
I admit myself incapable to pay regards in words to the affection, caring,
encouragement and dedications of my parents and brother who instilled in me
confidence, curiosity and taught me to dream big.
“Anything worth doing is worth doing poorly--until you can learn to do it well”
Zig Ziglar

"

!!!"

Abstract
Herpes simplex virus (HSV) infection of the eye results in chronic
immunopathological response in corneal stroma orchestrated by CD4 T cells. Due to its
neurotrophic nature, HSV can also invade brain and leads to deadly encephalitis. HSV
infection of the eyes leads to corneal neovascularization (CV), which is an important step
in the pathogenesis of herpetic stromal keratitis (HSK), an important cause of human
blindness. This study was undertaken to investigate the contribution of miRNAs and
Robo4 signaling in HSK. The role of miR-132 and miR-155 was evaluated. In the first
chapter, we review literature regarding the contribution of miRNAs in several human
diseases and speculate about the role of those miRNAs in herpes viral latency and HSK.
We also discuss involvement of Robo4 signaling in the context of pathological
angiogenesis.
In the second chapter, we show that HSV infection of the eyes of mice leads to
appearance of Robo4+ blood vessel endothelial cells in corneas but levels of Slit2 (a
ligand for Robo4 receptor) were minimal. The provision of exogenous Slit2 protein
reduced CV following HSV infection.
In the third chapter, we report the role of miR-132 in angiogenesis following
ocular HSV infection. We observed VEGF and IL-17 driven upregulation of miR-132
during HSK. miR-132 was shown to augment VEGF induced angiogenic responses and
blockade of miR-132 using antagomir nanoparticles reduced pathological angiogenesis in
eyes after HSV infection.
In the fourth chapter, we analyzed the involvement of miR-155 after ocular
infection with HSV. The mice unable to produce miR-155 were found to be highly
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susceptible to encephalitis after HSV infection with the majority of mice dyeing by day 9.
We further show that virus replication in brain was responsible for death in miR-155 null
mice. When T cell responses were measured, miR-155 knockout animals demonstrated
attenuated CD4 and virus specific CD8 T cell immunity. Additionally, we also evaluated
the role of miR-155 in HSK. miR-155KO survivors from herpes simplex encephalitis
were relatively resistant to HSK. In conclusion, we demonstrated that the miR-155 is a
regulator of herpes simplex encephalitis but it promotes inflammation during HSK.
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Background and overview
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Background and overview are modified from a review accepted in IOVS by Sachin
Mulik, '!(()*+)#,-".)*/,",0(".,--1"2"345+*6
Mulik S, Bhela S, Rouse BT. Potential function of miRNAs in herpetic stromal keratitis.
Invest Ophthalmol Vis Sci. 2013: in press. Copyrights held by ARVO.

Potential function of miRNAs in herpetic stromal keratitis

Abstract
MicroRNAs (miRNAs), the newly discovered regulators of gene expression, act
by promoting degradation of mRNA and by inhibiting protein expression. Dysregulation
of miRNA expression has been noted in an expanding number of diseases and in some
instances manipulating miRNA expression holds promise as a new form of therapy.
Herpetic stromal keratitis (HSK) is an important vision impairing lesion and currently
any role that miRNA dysregulation plays during its pathogenesis is only just beginning to
be investigated. In this review we discuss the likely participation of specific miRNAs
during HSK and discuss the prospect of modulating their expression as a means of
therapy.

Introduction
The discovery of a novel mechanism of gene regulation by miRNAs in nematodes
by Ambros and colleagues1 stimulated an intense search for similar regulatory
mechanisms in mammalian cells. The search has yielded abundantly with at least 800
different miRNA species identified with many of them dysregulated in metabolic
pathways that result in neoplasia, autoimmunity and an expanding number of other
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human diseases. In several instances either restoring miRNA levels or blocking their
activity represents a valuable means of therapy. Currently our understanding of miRNA
involvement during the pathogenesis of stromal keratitis caused by herpes simplex virus
(HSV) is very much in its infancy. This topic is discussed along with a speculative
assessment of the prospects of manipulating selected species of miRNAs as a therapeutic
maneuver that could reach the clinic.

What are microRNAs?
miRNA’s are genome encoded small, single stranded RNAs that post
transcriptionally down regulate gene expression either by degradation or translation
repression of the target mRNA. All canonical miRNA biogenesis process begins in the
nucleus where stem loops in the pri-miRNA are recognized by the enzyme Drosha and its
cofactor DGCR8, which cause nuclear cleavage to result in 60 nt precursor called premiRNA (figure 1.1). The pre-miRNA is exported to the cytoplasm with the help of
Exportin 5 and further processed with the help of another enzyme, Dicer. The Dicer
reduces the RNA size further to about 21 nt and also helps in the loading of the miRNA
single strand into the miRNA-induced silencing complex (miRISC). The miRNA guides
the miRISC to the target mRNA and the degree of complementarity between the miRNA
and the target mRNA determines the fate of the mRNA. If the two have high
complementary sequences the target mRNA is degraded by miRISC consisting of
Argonaut proteins. If there is only partial complimentary sequences between the miRNA
and the target mRNA, this would result in transcriptional repression by several miRISC
complexes bound to different sites on the target mRNA. Accordingly, miRNAs usually
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act to fine tune gene expression rather than to act as on/off switches. It is important to
note that not all cellular miRNAs use the canonical pathways, there are few other
mechanisms used by cells to generate functional miRNAs which have been reviewed in
detail by others2 and theses are not discussed herein.
Most miRNA genes are expressed under control of their own promoters and
regulatory sequences and act alone in gene regulation. However, others are arranged in
clusters and are expressed and function together (for example the miR-19-92 cluster).
The impact of miRNA expression during human and animal diseases has become known
from a variety of experimental approaches. These have included measuring the
consequences of gene knockout or over-expression, as can be done in experimental
rodent studies. Alternatively, miRNA expression can be reduced in vivo by antagomir
(miRNA inhibitory sequences) nanoparticle approaches, or be enhanced either by
administrating miRNA in nanoparticles, or by causing their biosynthesis using vectors
encoding miRNAs.

Herpetic Stromal keratitis: Role of Robo4 signaling and microRNAs
Infection with HSV generally leads to lesions on surface structures that include
the cornea of the eye. The infection can be acute, involving largely the epithelium and
resolve quite quickly, especially if treated with antivirals. Some cases, however, result in
chronic lesions that involve the corneal stroma and these impair vision and can even
result in blindness. HSK lesions in humans are commonly the consequence of one or
more episodes of HSV reactivation from latency3. The tissue damage that occurs in HSK
is thought to result in large part from the host inflammatory reaction and residual scarring
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set off by the infection. The strongest case that tissue damage in HSK represents an
immunopathological response to infection comes from animal studies, particularly the
mouse4. Such studies have identified several essential steps in lesion pathogenesis some
or all of which could be subject to regulation by yet to be identified miRNA species.
Several miRNAs are expressed by healthy mouse corneas under physiological
conditions5. Among these miR-132, miR-182 and miR-1 are expressed at low levels,
miR-146b shows intermediate expression while miR-21, miR-23b and miR-24 are
expressed at high levels in corneas. However, their contribution in modulating critical
events in corneal immunopathology during HSK remains largely unknown. The details of
HSK pathogenesis have received some recent reviews6, 7 and herein we mention only a
few essential points. Firstly, the inciting HSV infection in humans usually derives from a
breakdown of latent infection in the trigeminal ganglia, which is caused by exposure to a
variety of stressful stimuli. Accordingly, understanding how to sustain latency and
prevent reactivation is an important issue, and miRNAs could influence these events.
Early steps following HSV infection largely represent the response of innate
defenses and these may be sufficient to control virus before significant inflammatory
lesions occur. The overt HSK lesions appear to be inflammatory reactions orchestrated
mainly by T cells, particularly CD4 T cells of the Th-1 subset8. However, the principal
tissue damage and resultant corneal scarring is mainly attributed to inflammatory
products derived from nonlymphoid inflammatory cells such as neutrophils and
macrophages9, 10. Finally, the onset and extent of HSK lesions is influenced by the
neovascularization that occurs in the normally transparent avascular cornea11.
Understanding how to limit and resolve corneal neovascularization (CV) is an important
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therapeutic objective. As we discuss, the CV process is subject to control by one or more
species of miRNAs with a recent publication implicating the relevance of miR-13212.

miRNAs and Latency
The hallmark of all herpes virus infections is their ability to persist indefinitely in
the body in a state called latency. In the case of HSV, latency is maintained in neuronal
tissue, which with ocular infection means the trigeminal ganglion. During latency, the
virus produces no proteins so the agent may be invisible to the adaptive immune system.
Unfortunately, latency terminates in occasional neurons, which is probably a continual
process13. Productive replication occurs in such neurons and virus disseminates to
peripheral sites where it can cause recurrent lesions. It is conceivable that the regulatory
effects of miRNAs could influence the initiation, maintenance and breakdown of latency,
as well as whether or not the productive infection is sufficient to induce lesions. All of
these points here have yet to be firmly established.
With regard to the establishment of latency, HSV itself encodes a number of
miRNAs and these could influence the extent to which either latent or productive
infection of neurons occurs14. For example, the transcript expressed uniquely during
latency, LAT, serves as a primary miRNA precursor that encodes four distinct miRNAs
in HSV infected cells. One of these miRNAs, mir-H2-3p, can influence the expression of
the viral immediate early gene ICP014. Another miRNA, miR-H6, which lies upstream of
the LAT promoter, modulates the expression of ICP414. These observations came from in
vitro transfection assays, but if, as is likely, the same effect occurs in vivo, the miRNA
regulation could be highly relevant since both ICP4 and ICP0 proteins are involved in the
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initial phases of productive replication following primary and recurrent infections15, 16
Conceivably, virus encoded miRNAs could influence the amount of ICP4 and ICP0
expression in a latently infected neuron and this might determine if the productive cycle
is initiated. However, viral encoded miRNA regulation of HSV latency in vivo remains
an unresolved and debatable issue17, that merits more investigation.
Perhaps more amenable to therapeutic manipulation to influence latency will be to
identify any host encoded miRNAs that are responsible for maintaining latency and
which may lose this function in response to circumstances that cause reactivation. Such
circumstances include changes in hormone levels caused by stress or other events,
changes in immune status and exposure to UV irradiation being among the most
investigated. The herpetic recurrences that follow stressful experiences could be mediated
by changes in glucocorticoid levels and many studies have documented that
glucocorticoids can influence miRNA expression18. For example, glucocorticoids can
cause upregulation of the miRNA clusters miR-15/16 or miR-23319, but as yet none have
been related to latency. It would be of interest to determine if any changes of these
miRNA clusters precede the onset of viral reactivation. Additionally, glucocorticoids may
also influence gene expression changes by histone modifications, an event also
implicated in the maintenance of latency20. The glucocorticoid binding to cytoplasmic
glucocorticoid receptors triggers events that lead to induction of some anti-inflammatory
genes. These effects occur in part via recruitment of histone modifying transcriptional
coactivators and other cofactors to glucocorticoid responsive elements in the responsive
genes21. Moreover, glucocorticoid signaling can recruit histone deacetylases to the NFkB
complex and inhibit inflammatory gene expression22. These epigenetic events influenced
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by glucocorticoids could be caused by miRNA expression changes. For example, miR449 and miR-1 are involved in regulating the activity of histone acetylation23, 24. It
remains to be seen whether glucocorticoids may promote virus reactivation via changing
the levels of histone modification associated miRNAs (fig 1.2).
Another event that often causes the onset of recurrent herpes lesions is exposure
to excessive sunlight, such as sunburn. Exposure to UV light can also trigger reactivation
of HSV in a keratitis model in mice25. How UV irradiation or sunburn induces herpes
virus reactivation remains unclear, but recent reports indicate a potential role for miRNAs
in this process. For instance, the knockdown of Ago2 and Dicer, essential components of
the miRNA processing pathway, reduces survival of HELA cells exposed to UV
radiation26. This could mean that miRNAs play a critical role in UV induced cell cycle
events and apoptosis. Perhaps of more relevance, dysregulation in miR-21, miR-203,
miR-205, miR-24, let-7a and miR-376b is observed in murine epidermal tissue and
human kertatinocytes upon UV exposure27. At least two of these, miR-21 and miR-2428,
29

, can influence CD8 T cell functionality which, as mentioned subsequently, may

participate in the maintenance of latency30, 31 (fig 1.2).
Another well studied situation that may influence the stability and breakdown of
latency is immune status. For example, immunosuppressed patients are more likely to
suffer herpes recrudescence with severe lesions occurring in those with AIDS32. As
discussed subsequently, miRNA are known to influence the functional capacity of both
innate and adaptive immune components. The role of innate immune events in the control
of latency has received minimal attention, but there is strong evidence that the functional
competence of viral specific CD8 T cell responses in the trigeminal ganglion influences
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the stability of latency30, 31. Currently, we do not know if miRNA dysregulation impacts
on the immune control of latency, but this topic is under active investigation by many
groups that include our own.

miRNAs, Robo4 signaling and angiogenesis
The cornea’s function depends on its transparency since it must minimally
interfere with the passage of light to the retina. This may be one reason the normal cornea
lacks a blood vasculature since vessels diffract light. However, a significant consequence
of HSV ocular infection is that pathological angiogenesis occurs, a process driven and
facilitated by many factors6. A major angiogenic factor involved in corneal
neovascularization (CV) is VEGF and counteracting VEGF and events set off when it
binds to its specific receptors represents a valuable means of therapy33. We evaluated the
role of anti-angiogenic roundabout 4 (Robo4) signaling in HSK. Robo4 is a guidance
molecule expressed in brain that helps migration of neurons. But when expressed in
blood vessels, it regulates angiogenesis34, 35. Slit2, a ligand for Robo4, when binds to
trans membrane Robo4 receptor on blood vessel endothelial cells halts VEGF signaling
in cancer systems and retinal models36,

37

. We also observed Robo4+ blood vessel

endothelial cells during HSK but the expression levels of Slit2 were found to be minimal
in infected corneas. The provision of additional Slit2 protein resulted in significantly
reduced CV after ocular HSV infection38. It remains to be seen whether additional
angiogenesis regulatory mechanisms help to fine tune HSK pathological process.
Pathological angiogenesis is also a major problem in neoplastic diseases and
several species of miRNAs show changes that may account for the neovascularization.
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The miRNA that showed the largest change of expression during angiogenesis was miR13239. We have also shown that miR-132 is also upregulated in animals with CV
following HSV infection12. In the HSV system, the upregulation of miR-132 may be in
part the consequence of stimulation, by an as yet unidentified mechanism by IL-17, a
cytokine produced early in HSK pathogenesis by gamma delta cells of the innate immune
system40. The upregulated miR-132 appears to act to augment VEGF signaling via an
inhibitory effect on a negative regulator of VEGF function, Ras-GAP39. Of interest,
inhibiting the expression of miR-132 using antagomirs in the form of nanoparticles was
an effective means of diminishing CV as well as reducing the severity of HSK (figure
1.3) (Table 1.1). Additionally, miR-132 blockade results in potent reduction in
pathological angiogenesis in retinal models (Westenskow PD, et al. IOVS 2012; 53:
ARVO E-Abstract 4120). Of note, this modality seems to work better than VEGF trap
approaches and resulted in fewer off target effects and lower compensatory increases in
angiogenic molecules, which is often the case with VEGF inhibition approaches41. It is
also to be noted that miR-132 function depends on context. Thus, miR-132 promotes IFN
production in Kaposi sarcoma herpes virus infected lymphatic endothelial cells42,
regulates dendritic maturation in newborn neurons43. However, while it exerts antiinflammatory effect at neural immune interface44. Although we realize that miR-132 has
an antiangiogenic function during HSK it is also possible that it interacts with other
miRNAs in its modulation of tissue damage.
In addition to VEGF, matrix metalloproteinase-9 (MMP-9) and other
metalloproteinases play pivotal roles in promoting pathological blood vessel development
during HSK45. Recent reports indicate that the regulation of MMP-9 expression involves
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modulating effect by miRNAs. Accordingly, miR-885-5p, miR-491-5p, miR-212 and
miR-132 negatively regulate the levels of MMP-9 expression in mammary glands and in
cancer models46, 47. Our recent reports suggest upregulation of miR-132 and MMP-9 in
corneas during HSK12, 48. miR-132 blockade induced reduction in CV and expression of
miR-132 in blood vessel endothelial cells while MMP-9 in neutrophils make MMP-9 an
unlikely target of miR-132 during HSK. While simultaneous expression of Ras-GAP and
miR-132 in blood vessel endothelial cells from HSK or retinal models sets the angiogenic
wheels in motion. However, targeting of MMP-9 with one or more species of inhibitory
miRNAs with antagomir nanoparticles might represent a useful approach to therapy
(Table 1.1).
Almost certainly there are additional miRNAs that influence the many stages of
CV. For example it is known that the activity of VEGF in the cornea is limited by being
bound to a soluble form of one of its receptors49. HSV infection disrupts the balance
between VEGF and its soluble receptor48, a process that likely involves expression
changes in miRNAs. Additional events that could be regulated by miRNAs include
disruption of blood vessel endothelial junctions, pericyte detachment, invasion of
endothelial cells towards the center of the cornea as well as their proliferative effects. It is
also likely that miRNAs fine tune the activity of apoptotic/anti apoptotic molecules in
pathological blood vessel endothelial cells. Accordingly, the provision of appropriate
miRNAs may induce apoptosis of endothelial cells and this may result in regression of
established blood vasculature during HSK. Furthermore pathological blood vessels,
which occur in corneas during HSK, are leaky and whether miRNAs influence leakiness

"

%%"

of such vessels by modulating the activity of src kinases or by regulating the functionality
of proteins involved in maintenance of endothelial junction integrity requires exploration.

miRNAs and Inflammation
Several types of innate immune sensors are triggered when HSV infects the
cornea and many molecules with diverse function are rapidly produced. These include
pro-inflammatory cytokines, chemokines, interferons and angiogenic factors such as
VEGF. Among the best studied innate sensors are the toll like receptors with TLR2,
TLR3 and TLR9 all involved as HSV sensors50, 51. Additional intracellular sensors may
also recognize HSV and these include the recently described sensor STING that
recognizes HSV induced membrane fusion and inflammasomes which lead to production
of the pro-inflammatory cytokine IL-1b52-54. The innate recognition phase sets the scene
for both

infection control, mediated by interferons and innate effectors such as

granulocytes, macrophages and NK cells, as well as establishing conditions that result in
tissue

damage

orchestrated

by

adaptive

components

of

immunity.

Most

persons with HSV keratitis resolve infection with little or no stromal disease. Those less
fortunate develop HSK with this outcome most likely to occur after one or more
recurrences from latency. Why individuals differ in their response pattern to HSV
infection remains poorly understood but differential regulation of innate and adaptive
immunity by one or more species of miRNA is a likely possibility that merits
investigation.
With regard to the extent of innate immune sensing, evidence accumulates
showing that TLR function is subject to control by numerous miRNA species. As lucidly
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reviewed by O'Neil and colleagues55, miRNAs may regulate the strength, location and
timing of TLR responses and also appear to control the switch from an early innate
immune induced pro-inflammatory response to conditions that represent the resolution
phase of the inflammatory process. In fact, at least 10 miRNAs are upregulated when one
or more TLRs engage their ligands and others are down regulated. Apparently the TLRs
themselves are not targeted by miRNAs and regulation mainly affects the activity of
signaling molecules55. In this context, TLR signal transducers such as MyD88, IRAK,
TAB, TRAF6, IKK are all targets of one or more species of miRNAs. In addition,
transcriptional factors induced by TLR ligation are subject to miRNA regulation and
some miRNAs also degrade the products of TLR signaling55. One such miRNAs is let-7
that binds to the mRNA of IL-6 and decreases expression of this cytokine which is a
major participant in HSK pathogenesis and also a stimulant of the angiogenic factor
VEGF56. Additionally, other cytokines such as TNF-!, IL-10, IL-12 and IFN-" are
directly repressed by miRNA action55. However, what role if any these aforementioned
miRNAs play during the innate phase of HSK pathogenesis remains to be seen.
Additional components of innate responses to HSV include granulocytes,
macrophages and NK cells. The function of all of these cell types is influenced by
miRNA expression57-59. For example, miR-223 regulates the proliferation and activation
status of neutrophils60. Furthermore, its also conceivable that miRNAs are involved in
regulating tissue damaging molecules such as the production of reactive oxygen and
nitrogen radicals by neutrophils and the generation of neutrophil extracellular traps.
Macrophage function during infection is influenced my several miRNAs that include
miR-155, miR-146, miR-132, miR-147, miR-9, let-7e, miR-27b and miR-125b61,
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62

. Similarly NK cell killer function, such as granzyme activity, is influenced by miR-155

and miR-27a*63, 64.
Although it is still early days, it has become evident that miRNAs derived from
innate immune cells, and perhaps exported from such cells in the form of exosomes65, are
important regulators of inflammation and the miRNAs also influence the balance of
adaptive immune responses that determine whether immunity or tissue damage ensues.
Indeed, the enforced expression of TLR induced miRNAs might well turn out to be
useful negative regulators of the inflammatory process, as well as tools to shape the
desired pattern of adaptive immunity to one that has minimal tissue damage.
As mentioned in a previous section, the tissue damaging events in HSK are
orchestrated predominantly by effector CD4 T cells with the actual damage mainly
mediated by neutrophils and macrophages9,

66, 67

. Multiple miRNAs are known to

influence the induction and effector function of T cells, the recruitment and activation of
inflammatory cells as well as the participation of additional cell types such as regulatory
T cells involved in lesion resolution. The topic is complex and fast moving. In
consequence, we mention only what may be the most pertinent miRNA expression
events that impact on the pathogenesis of HSK and which represent promising candidates
for therapeutic manipulation to change the outcome of disease.
The miRNA miR-23b, generally implicated in liver regeneration68, 69, is a likely
candidate since it also acts as a critical regulator in several autoimmune syndromes in
humans and mice whose pathogenesis has similarity to HSK70. Accordingly, miR-23b
normally plays an anti-inflammatory role by inhibiting the transcription factor NFkB that
in turn regulates the production of numerous proteins involved in tissue damage, as well
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as the recruitment of pro-inflammatory cells. The expression of miR-23b is down
regulated by a still poorly understood mechanism when the pro-inflammatory cytokine
IL-17 binds to its receptor. As a consequence, NFkB becomes hyperactivated and
inflammation progresses. Although HSK is mainly orchestrated by inflammatory Th1
cells, the cytokine IL-17A produced by innate cells does play a prominent role during the
onset of HSK and may also participate in neovascularization40, 71. Thus, it is conceivable
that miR-23b dysregulation occurs during HSK and this may influence the severity of
lesions that ensue. This aspect merits investigation, as does the prospect that
administration of additional miR-23b may represent a useful adjunct to therapy (Table
1.1).
miR-155 is another miRNA frequently implicated in inflammatory lesions and
serves to positively regulate inflammation72-74. It is also required for normal immune
function75, 76 as well as for generation of pathogenic T cells

77

and act as an oncomir in

various cancers78, 79. Animals deficient in miR-155 because of gene knockout (KO) are
resistant to the induction of some autoimmune diseases72, 77. We have also observed that
miR-155 KO animals develop significantly reduced HSK lesions, although they become
highly susceptible to virus induced encephalitis (S. Mulik, S. Bhela and B.T. Rouse,
unpublished observations). The miR-155 may influence tissue damage in several ways
that include regulating the production of critical chemokines such as those for neutrophils
which play a prominent role in HSK pathogenesis73. Our preliminary results in the HSK
system indicate that chemokines such as the neutrophil attracting CXCL1, are reduced in
miR-155 deficient animals. In addition, as is shown in some autoimmune models, miR155 deficiency may also result in the increased production of the critical anti-
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inflammatory mediator IL-10, as well as reduced generation of Th1 and Th17 effectors
that orchestrate HSK lesions77. In some inflammatory and autoimmune settings, loss of
miR-155 also results in profound reduction in the inflammatory milieu as well as tissue
damage74. Since counteracting T cell function and inflammation would be useful to limit
tissue damage, administering antagomirs to diminish miR-155 expression may be a
valuable approach to achieve this objective during HSK, as we are currently evaluating
(Table 1.1).
There are other miRNAs that we speculate may significantly influence the
pathogenesis of HSK. In this regard, miR-29 was recently shown to target Tbet and
Eomes transcription factors, both of which promote IFN-" production by Th1 cells80,
central orchestrators of HSK pathogenesis. Similarly, miR-326 and miR-301a are
involved in the generation of Th-17 cells, a subset recently shown to influence the later
stages of HSK40. Inhibition of miR-326/301a resulted in attenuated EAE lesions in mice
via effects on Th-17 cells81, 82. miRNAs are also known to be involved in sequential steps
of T cell proliferation. For example, miR-142-3p/5p, miR-17 and miR-20a inhibit T cell
activation83, 84. On the other hand, IL-2 induced miR-182 degrades Foxo 1 and promotes
clonal expansion of activated helper T lymphocytes85.
It is now realized that fully differentiated T cells, once considered a stable
population, may take on other activities depending on environmental cues. For example,
Tregs can lose their regulatory function and adopt effector phenotypes86. It appears that
changes in miRNA expression may be involved in this cellular functional plasticity87. For
example, in response to retinoic acid and TGFb, Tregs increase miR-10a expression that
limits their conversion into follicular helper T cells and Th-17 cell subsets. Whether and

"

%:"

how miRNAs influence various stages of T cell activation or T cell flexibility during
HSK is largely unknown (Table 1.1).

miRNAs in anti-inflammation and resolution
The aim of all research on inflammatory diseases is to discover optimal ways to
resolve lesions and understand how they function at a mechanistic level. Under natural
circumstances, inflammatory responses are usually resolved either because the inciting
stimuli are removed and/or because the balance of host events changes. Such changes
could be influenced, at least in part, by dysregulation of one or more species of miRNAs.
Several host events can push inflammation towards resolution. These include the
expansion of regulatory T cells, the increased activity of several cytokines particularly
IL-10 and TGFb, the production of one or more species of host galectins as well as
multiple specialized proresolving mediators derived from polyunsaturated fatty acids.
How miRNA changes relate to the increased activity of these anti-inflammatory and
inflammation resolving events is beginning to be unraveled, at least for some of them.
Two such candidates are miR-146a and miR-21 that play prominent roles in protecting
tissues from inflammatory damage62.
miR-146a exerts this regulatory effect by policing NF-#B dysregulation. In the
context of innate immunity, miR-146a inhibits TLR signaling and NF-#B activation and
dampens the production of pro-in$ammatory mediators such as IL-6 and TNF-!88. A
diminished miR-146a response also results in malfunction of the adaptive immune
responses. Of note, regulatory T cells express high levels of miR-146a and Treg specific
deletion of miR-146a expression leads to severe autoimmune disease due to uncontrolled
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Th-1 responses89. This further corroborates a regulatory role of miR-146a in restraining
inflammation and maintaining peripheral tolerance. In addition miR-146a was implicated
in resolving both CD4 and CD8 T cell mediated immunopathological responses90. In
mice, TCR stimulation induced expression of miR-146a and T cell specific miR-146a
deficiency resulted in hyperactive acute antigenic responses, chronic inflammatory
autoimmune responses as well as T cell mediated autoimmune disease90. It will be of
interest to see what effects miR-146a overexpression will have on the balance between
protective Tregs and eye damaging Th-1 cells during HSK. We speculate that the potent
regulatory environment induced by miR-146a may hamper lesion development (Table
1.1). Moreover, dampening of pro-inflammatory milieu by administering additional miR146a could represent a useful form of therapy.
Another miRNA likely involved in resolution is miR-21. This miRNA halts
inflammation in various models partly via its ability to induce IL-1091, 92, a molecule
previously shown to suppress HSK lesions93. However, miR-21 may enhance vascular
inflammation in atherosclerosis94. miR-21 may also shift the Th1/Th2 balance towards
the Th2 type95 with miR-21 deficient mice demonstrating enhanced Th1 associated
responses96. Conceivably, overexpression of miR-21 could help to modulate Th1
mediated tissue damage during HSK an issue that merits further investigation (Table 1.1).
An additional approach to modulate the severity of inflammatory diseases is to
expand or activate regulatory T cells whose activity is also influenced by expression
levels of several miRNAs97, 98. These include miR-10a, miR-146a and miR-15589, 99-101,
but their contribution in modulating ocular damage is yet to be analyzed. Conceivably,
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the above mentioned miRNAs will help shift the balance towards resolution events in
tissue damaging settings.
In the resolving phase of inflammation, changes in expression of several
mediators occur. One prominent change is in the lipid mediators derived from
polyunsaturated fatty acids. Thus whereas during the pro-inflammatory phase
leukotrienes and prostaglandins predominate, during resolution there is a switch to lipid
mediators referred to as specialized prosesolving mediators (SPM)102. This switch may be
regulated, at least in part, by changes in miRNA expression. For example, miR-292-2
levels increase for reasons that include neutrophil death with miR-292-2 targeting the
mRNA of the lipoxygenase enzyme responsible for generating the pro-inflammatory
leukotrienes103. Additionally miR-292-2 increases, by an unknown mechanism, the
synthesis of SPM such as resolvins and protectins. In HSK, where in some
instances resolution can be delayed, it is conceivable that miR-292-2 levels are
suppressed perhaps in situations when viral replication levels are elevated.
The observation that SPMs appear to account for resolution under natural
circumstances has led to the development of synthetic formulations that are proving
valuable to control inflammatory lesions that include HSK104, 105. It has also become
evident in recent studies from the Serhan group that levels of multiple miRNAs change in
response to synthetic SPM therapy106. For example, resolvin administration fine-tunes
levels of miRNAs such as miR-21, miR-146b, miR-208a and miR-292-2 in various tissue
damaging settings106,

107

. These miRNAs act by changing the expression of several

inflammatory mediators. For example, miR-21 and miR-208a induce IL-10 production
during the resolution phase thus exerting strong anti-inflammatory effect. miR-146b also
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regulates levels of IL-8 and RANTES, both powerful chemo attractants that recruit
leukocytes into in$amed areas, while miR-292-2 induces the production of more SPM.
We speculate that the provision of SPM during HSK may act by inducing the expression
of pro resolution miRNAs that include miR-21, miR-146b, miR-292-2 while levels of
inflammatory and angiogenic miRNAs (miR-155 and miR-132) might diminish (fig 1.4)
(Table 1.1). Our unpublished observations support this claim. Whether any group of
miRNAs are sufficient to activate a resolution program is currently not known. If it can
be accomplished the inclusion of pro-resolution miRNAs would be valuable when
designing therapeutics to counteract HSK lesions.

Potential of miRNA targeting
Manipulation of disease associated microRNAs offers unique opportunities but
poses challenges as regards of delivery, target site accessibility and off target effects.
Progress on this topic has occurred with several reports showing amelioration of diseases
via blockade of miRNAs using modified antagomirs as is the case with locked nucleic
acid (LNA) or antagomirs given in nanoparticles108, 109. Our own study evaluated the
potential of miR-132 inhibition using antagomir-132 histidine lysine nanoparticle
approaches that led to potent reduction of CV. This was also recently confirmed in retinal
models by Martin Friedlander and David Cheresh groups who showed that nanoparticle
mediated miR-132 blockade is more efficacious (Westenskow PD, et al. IOVS 2012; 53:
ARVO E-Abstract 4120) than conventional VEGF inhibition therapies and results in
lower off target effects and fewer compensatory increases in angiogenic genes compared
to VEGF targeting. Several other recent reports support miRNA inhibition approaches to
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modulate disease pathologies. For example, miR-122 shows effects against Hepatitic C
virus infection110; miR-155 is effective in the inflammatory disease models, EAE111, 112 as
well as against B cell lymphoma79,

113

. Additionally, miR-21 is effective to inhibit

lupus28. We are investigating the potential of slow antagomir release eye drop formulated
nanoparticles to intercept HSK pathogenesis and believe that the cocktail of miRNAs
given in nanoparticles locally may confer therapeutic benefit against HSK.

Concluding remarks
Although published information about the regulatory role of miRNAs during HSK
is minimal we can surmise that multiple miRNAs are likely to influence all of the many
events that occur during HSK pathogenesis. We can also surmise that changing miRNA
responses could represent a useful approach to therapy especially because several phases
of HSK could be targeted simultaneously using cocktails of multiple miRNAs mimics
and antagomirs. The major practical problem would be how to administer the cocktail
and how frequently this must be done to achieve therapeutic efficacy. There have been
some reports that show the ease of delivery of siRNA to localized areas such as the eye,
lung and skin and these siRNAs were shown to be effective in in vivo silencing114,115. In
fact most of these siRNAs are under clinical trials. Although only one such miRNA
targeting drug is in clinical trial (miravirsen). It is conceivable many more miRNA
intervention therapies could enter clinic in the near future.
It is also likely that the composition of the therapeutic cocktail would need to differ at
different phases of HSK lesions. Most likely treatment close to the onset of lesions would
stand the best chance of success. We would speculate that using miRNAs or antagomirs
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to increase IL-10 expression, to block the recruitment of inflammatory cells to the
corneas and to limit the extent of CV would be successful strategies. At later stages
switching the inflammation to the resolution phase would be desirable as might be
achieved by changing the expression of miRNAs involved in SPM production. Although
therapy with miRNA has therapeutical advantages, it remains to be seen if the approach
would be practical or economical compared to traditional therapies in current use.
Answering these questions will require further research. Optimistically nanoparticles
containing multiple miRNAs and antagomirs would be administered once or twice daily
and be therapeutically effective.
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Appendix
Table 1.1: Speculative role of miRNAs, their blockade/overexpression and reduction
in HSK lesion severity (Mild +, Moderate ++, Severe +++).
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Figure 1.1. miRNA biogenesis: The generation of miRNAs involves nuclear and
cytoplasmic processing steps. In the nucleus, pri-miRNAs, transcribed by RNA
polymerase from DNA, are processed by Drosha into pre-miRNAs which are then
transported to cytoplasm via exportin 5. Once in cytoplasm, these pre-miRNAs are
recognized and cleaved by Dicer into 20-22 bp duplexes that enter RISC. In RISC,
passenger strand is cleaved while guide strand directs RISC machinery to target mRNAs
resulting
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Sunburn
? miR-21, miR-203, miR-203,
miR-24, let-7a, miR-376b

Virus
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(miR-44 & miR-1)

? (miR-21 and miR-24)
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Figure 1.2. Speculative role of miRNAs in HSV-1 reactivation from latency. After
primary infection, HSV-1 becomes latent in trigeminal ganglia. Certain conditions such
as sunburn, stress, impaired T cell responses, immunosuppression can reactivate virus to
come to the peripheral sites (eyes, oral mucosa) to induce lesions. miRNAs may regulate
all of these above mentioned stimuli. Sunburn can trigger HSV reactivation and it
involves changes in expression levels of miRNAs (miR-21, miR-203). Likewise, stress
induced glucocorticoids induce changes in miRNAs (miR-15/16 and miR-223) and also
lead to epigenetic modifications, a process which involves miRNA change (miR-44 and
miR-1) and is implicated in maintenance of latency. CD8 T cells patrol trigeminal ganglia
and inhibit HSV reactivation but functionality of CD8 T cells can also be modulated by
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miRNA activity (miR-21 and miR-24). The role of HSV encoded miRNAs in HSV
reactivation remains unknown so far.

Figure 1.3 Illustration of antagomir-132 mediated inhibition of corneal
neovascularization (CV). Left panel describes outcome (CV) in HSV infected untreated
mice: HSV infection leads to upregulation of IL-17 in corneas. IL-17 (along with IL-6
and virus infected epithelial cells) increases VEGF (probably via increasing IL-1b, IL-6
and Cxcl1) levels in the eyes. VEGF thus acting through VEGFR2 receptors on the blood
vessel endothelial cells upregulates miR-132 expression via CREB transcription factor.
MiR-132 removes RasGAP (intrinsic inhibitor of Ras) leading to activation of Ras and
CV. Right panel describes modulation of CV by miR-132 silencing: Administration of
antagomir-132 nanoparticles leads to deposition of antagomir-132 cargo in blood vessel
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endothelial cells resulting in silencing of miR-132. This leads to higher levels of
RasGAP, which thereby inhibits angiogenic Ras activity resulting in inhibition of CV
(Reprinted from Am J Pathol 2012, 181:525-534 with permission from the American
Society

for

Investigative
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Figure 1.4. Specialized pro-resolution mediators (SPM) and miRNA mediated
resolution of HSV induced ocular inflammation: Speculations. The provision of SPM
during HSK may result in changes in levels of various miRNAs associated with
resolution. SPM could increase expression of miR-21 and miR-208a both of which
induce anti-inflammatory cytokine, IL-10. SPM can also increase miR-146b expression
and miR-146 lowers levels of IL-8, a chemokine crucial for neutrophil recruitment to
eyes. miR-292-2 induced by SPM gives positive feedback for more SPM production. The
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administration of SPM may also lower levels of miR-132 and miR-155 involved in CV
and inflammation respectively.
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Part II

Activation of endothelial roundabout receptor 4
(Robo4) reduces the severity of virus induced keratitis
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Research described in this chapter is reproduced from a publication accepted in Journal
of Immunology by Mulik S, Sharma S, Suryawanshi A, Veiga-Parga T, Reddy PB,
Rajasagi NK and Rouse BT.
Mulik S, Sharma S, Suryawanshi A, Veiga-Parga T, Reddy PB, Rajasagi NK, Rouse BT.
Activation of endothelial roundabout receptor 4 reduces the severity of virus-induced
keratitis. J Immunol. 2011 Jun 15; 186(12): 7195-204. Copyright 2011. The American
Association of Immunologists, Inc.
Abstract
Anti angiogenic molecules exert a feedback control to restrain pathological angiogenesis,
which include physical binding or inhibition of angiogenic signaling in blood vessel
endothelial cells. The latter is the case when Slit2 ligand dependent activation of the
blood vessel endothelial cell receptor roundabout 4 (Robo4) occurs. In this study, we
demonstrate that Robo4 receptors are up regulated following herpes simplex virus (HSV)
infection of the eye on the majority of the new blood vessel endothelial cells that occur in
the corneal stroma. However, expression levels of the ligand for Robo4 receptors, Slit2,
was not significantly increased during the disease process and the knockdown of Slit2
gene expression using lentiviral shRNAs had no effect on the extent of pathological
angiogenesis. In contrast, providing additional Slit2 protein by subconjunctival
administration resulted in significantly reduced angiogenesis. The Slit2 binding to Robo4
was shown to block the downstream VEGF signaling molecules Arf 6 and Rac 1 and
reduced the anti-apoptotic molecule Bcl-xL in blood vessel endothelial cells. Our results
indicate that augmenting the host Robo4/Slit2 system could provide a useful therapeutic
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approach to control pathological angiogenesis associated with HSV induced stromal
keratitis (SK).

Introduction
Ocular Herpes simplex virus (HSV) infection may result in a chronic immunoinflammatory lesion in the corneal stroma that often results in blindness (1-4).
Understanding the pathogenesis of stromal keratitis (SK) lesions has mainly come from
animal model studies, particularly using the mouse (5). Such studies have revealed that
neovascularization of the normally avascular cornea is a key event in SK pathogenesis (68). In consequence, understanding how to control pathological angiogenesis, which is
also a critical event in human SK, is relevant since it could result in improved therapy.
Many molecules induced in the eye in response to infection can contribute to
neovascularization with the VEGF family molecules, particularly VEGF-A signaling via
VEGFR-2 receptors, being the major stimulus for angiogenesis (9-11). Curiously, VEGFA is produced within the normal cornea, but it fails to drive blood vessel development
since it is bound to an excess of the soluble form of one of its receptors (12-14). Virus
infection results in the increased synthesis of VEGF-A as well as some other angiogenic
molecules (15, 16) and, in addition, causes the breakdown of the VEGF-A/soluble
receptor bond (Manuscript accetped for publication). Interference with VEGF levels, or
blocking the binding or signaling of receptors are the major approaches so far evaluated
to control pathological neovascularization (6, 7, 9, 17). However, the host itself also has
one or more means of shutting down VEGF induced angiogenesis (13). For example, the
Robo4 receptor that is expressed by endothelial cells in newly formed blood vessels can
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transduce signals to the cell that will negate or counteract the positive stimulus caused by
VEGF binding to its receptors (18, 19). Robo4 receptors can be activated by the host
ligand, Slit2, that is produced in some pathological lesions by vascular endothelial cells
(18, 20). Accordingly, the balance between the positive signals produced by VEGF may
become modulated and perhaps terminated by Slit2 induced Robo4 receptor activation. In
some circumstances, such as in laser induced retinopathy, Robo4 knockout mice revealed
an accelerated pathological angiogenesis process (18). Additionally, Slit2/Robo4
signaling reduced vessel permeability in the lung and other organs and protected mice
from a pathogen induced cytokine storm (21).
Currently, no reports have evaluated the relevance of the Slit2/Robo4 regulatory system
in an infectious disease that involves pathological angiogenesis. This issue is addressed
herein using ocular infection with HSV that causes neovascularization of the cornea and
the blinding lesion stromal keratitis. Our results show that following HSV infection,
Robo4 transcripts were significantly up regulated in corneal tissues with the majority of
endothelial cells of the newly developed blood vessels expressing Robo4 receptors.
However, the Robo4 ligand, Slit2 transcripts and protein were not significantly increased
after HSV ocular infection. This could mean that the amount of Slit2 available for
binding to Robo4 receptors was limited and that the Slit2/Robo4 host regulatory system
was not contributing to effectively control angiogenesis during SK. In support of this
notion, blocking Slit2 gene expression using lentiviral shRNA vectors had no effect on
the extent of angiogenesis, but in contrast, the provision of additional Slit2 protein by
sub-conjunctival injection significantly reduced neovascularization. The results of these
studies have therapeutic implications for the control of HSV-induced vision loss.
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Materials and Methods
Mice: Female 6-8 wks old C57 BL/6 mice were purchased from Harlan Sprague Dawley
Inc. (Indianapolis, Indiana, USA). All mice were housed conventionally in animal facility
at the University of Tennessee. All investigations followed guidelines of the Association
for Research in Vision and Ophthalmology resolution on the use of animals in research.
Virus: HSV-1 strain RE Tumpey was propagated in Vero cell monolayers (ATCC nol
CCL81). Infected Vero cells were harvested, titrated and stored in aliquots at -800C until
used.
Corneal HSV-1 infection and scoring: Corneal infections of mice were performed
under deep anesthesia. The mice were lightly scarified on their corneas with a 27-gauge
needle, and a 3 &l drop containing 104 PFU of HSV-1 RE Tumpey was gently applied to
one eye. The development of SK lesion severity and angiogenesis in the eyes of mice was
examined by slit-lamp biomicroscopy (Kowa Company, Nagoya, Japan). The scoring
system used was as follows: 0, normal cornea; 1, mild corneal haze; 2, moderate corneal
opacity; 3, severe corneal opacity; 4, opaque cornea and ulcer; 5, corneal rupture. The
severity of angiogenesis was recorded as described previously (22). According to this
system, a grade of 4 for a given quadrant of the circle represents a centripetal growth of
1.5 cm towards the corneal center. The score of the four quadrants of the eye were then
summed to derive the neo vessel index (range 0 16) for each eye at a given time point.
Sub-conjunctival injections: Sub-conjunctival injections were performed as reported
previously (22). Briefly, these injections were carried out using a 2-cm, 32-gauge needle
and syringe (Hamilton, Reno, NV) to penetrate the perivascular region of conjunctiva and
appropriate amount of Slit2 protein (R & D systems, Minneapolis, MN) was administered
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into sub-conjunctival space. Slit2 protein used in this study is a Gln26-Gln900 amino
terminal fragment, which is expressed in CHO cells. Mock treatment was given in control
mice.
Mice treatment with recombinant Slit2 protein: The mice ocularly infected with HSV1 RE Tumpey were separated into two groups. The Slit2 protein (1 &g) was given to one
group in 10 &l PBS sub-conjunctivally at 2 days p.i. with additional doses on alternate
days until day 12 post infection. The Slit2 treatment was begun at day 7 in another
experiment with additional doses on alternate days until day 13 post infection. Control
group received mock drug sub-conjunctivally with the same regimen for respective
experiment. These animals were carefully followed for the progression of angiogenesis
and SK development. All experiments were repeated at least two times.
Purification of endothelial cells: The excised corneas were pooled and digested with 60
U/ml Liberase for 35 minutes at 370C in a humidified atmosphere of 5% CO2. The single
cell suspension was prepared and stained with anti CD 31-FITC for 30 minutes on ice.
The FITC+ endothelial cells (CD 31+) were sorted using a FACS sorter. The purity at the
extent of 80-90% was achieved. These sorted endothelial cells were used for pull down
assays, for detection of Bcl-xL, cyclin D1 and caspase 3 proteins and for confocal
microscopy.
Confocal microscopy. For confocal staining, the purified endothelial cells were taken on
a slide using cytospin and fixed in 4% para!formaldehyde at room temperature for 10
min. The cells were blocked with 10% goat serum containing 0.05% Tween20 and 1:200
dilution of Fc block (Clone 2.42G2; BD Biosciences Pharmingen, San Diego, CA). Rat
anti!Robo4-PE (R & D systems, Minneapolis, MN) and Rat anti!CD31-FITC (Clone:
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390, BD Pharmingen) were diluted in 1% BSA containing 0.1% Triton!X and incubated
at room temp for 1 hr. After incubations, slides were washed several times with PBST
and mounted with Prolong gold antifade mounting media (Invitrogen) and visualized
under a confocal microscope.
Flow Cytometry: The corneal single cell suspensions were prepared following Liberase
digestion of corneas. These corneal cell suspensions were stained for different cell
surface molecules for FACS. Shortly, cell suspensions were incubated with CD45allophycocyanin

(30-F11),

CD11b-PerCP

(M1/79),

Gr1-PE

(1A8),

CD

4-

allophycocyanin (RM4.5), CD31-FITC (All from BD Biosciences Pharmingen) and
Robo4-PE (R & D systems, Minneapolis, MN) for 30 minutes on ice. Thereafter, cells
were washed thrice and resuspended in 1% para-formaldehyde. The stained samples were
acquired with a FACS Calibur (BD Biosciences) and the data were analyzed using the
FlowJo software.
Quantitative PCR (QPCR): Total mRNA was isolated from corneal cells using TRIzol
LS reagent (Invitrogen). The cDNA prepared using 1 µg of RNA was used for subsequent
analysis. QPCR was done using SYBR Green PCR Master Mix (Applied Biosystem,
Foster City, CA) with iQ5 real-time PCR detection system (Bio Rad, Hercules, CA). The
expression levels of Slit2 and Robo4 were normalized to %-actin with 'Ct method and
relative quantification between control and infected mice was performed using the 2!''Ct
formula.

The

primers

used

were

as

follows.

%-actin

forward

CTACCTCATGAAGATCCTGACC,

%-actin

reverse

GTCTAGAGCAACATAGCACAGC;

Slit2

forward

CCTTCTGAATGTACCTGCTTGG, Slit2 reverse GTAGTTAGAGAGTTCCTTCGGG;
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Robo4

forward

GACCTATATGTGTATGGCCACC,

Robo4

reverse

CTCTAGATGTTCCTTGTGGTCC, Cxcl2 forward CCAACCACCAGGCTACAG,
Cxcl2

reverse

CTTCAGGGTCAAGGCAAAC,

Nos2

forward

TGGATTGTCCTACACCACA and Nos2 reverse CTCCAATCTCTGCCTATCC. The
primers for Il1b, IFNg, Il6 and Cxcl1 were already available in the lab (Manuscript
accepted for publication in Journal of Virology).
Reverse Transcription Polymerase chain reaction (RT-PCR): RT-PCR for the
presence of Slit2 and Robo4 transcripts was done according to the manufacturers protocol
(Promega, Madison, WI). The amplified products were resolved on 1% agarose gel.
Primers

for

RT-PCR

were

as

follows.

%-actin

forward

CTACCTCATGAAGATCCTGACC,

%-actin

reverse

GGCATAGAGGTCTTTACGGATG;

Slit2

forward

GGGAACGACAGTTTCATAGGACTC,

Slit2

GTAGTTAGAGAGTTCCTTCGGG;
GGAGTGACCTTAAGATCTGGCAAC

reverse

Robo4
and

forward
Robo4

reverse

CTAGTAGCAGCAACCAGAGTAG.
Western blot analysis: The corneal cells were lysed and total protein in the supernatants
was quantified using BCA protein assay kit (Thermo scientific, Waltman, MA). Samples
were denatured in Laemmli buffer and resolved by SDS-PAGE and proteins were
transfered onto a PVDF membrane. The membrane was blocked with 5% BSA in Trisbuffered saline with Tween 20 at 40C overnight and subjected to incubation with specific
primary

and

secondary

antibodies.

Proteins

bands

were

visualized

using

chemiluminiscent HRP substrate (Millipore, Billerica, MA). After keeping in stripping

"

9>"

buffer for 10 minutes, the membrane was re-probed using anti %-actin antibody. The
antibodies used were as follows: goat anti mouse Robo4 (C-20), goat anti mouse Slit2
(D-16), anti %-actin (C 4), mouse Bcl-xL (4), mouse cyclin D 1(72-13G), goat caspase 3
(T-20), goat anti mouse IgG-HRP and donkey anti goat IgG-HRP (All these antibodies
were procured from Santa Cruz biotechnology), mouse Arf 6 (26186D) (Thermo
scientific, USA) and mouse Rac 1(89856D)(Thermo scientific).
Arf 6 activation assay: Arf 6 activation assays were performed as reported previously
(19). These experiments were carried out using Active Arf 6 pull down and detection kit
(Thermo scientific) according to manufacturer’s protocol. Briefly, resin slurry was added
to the spin cup in a collection tube and 100 µg GST GGA3-PBD fusion protein with 800
µg total protein (corneal cell lysate) was added to this slurry. This was incubated at 4oC
for 1 hour and finally 50 µl reducing sample buffer was added and GTP-Arf 6 was pulled
down and subsequently analyzed by WB. These experiments were repeated two times.
Rac 1 activation assay: The Rac 1 activation assays were carried out as described
previously (19). The EZ-Detect™ Rac 1 activation kit (Thermo scientific) was used to
isolate active Rac 1 from corneal cell lysates. The immobilized glutathione disc was place
into a spin column and 20 µg of GST-human Pak1-PBD was added to it. Immediately,
700 µg total protein (corneal cell lysate) was added to the spin column and it was
incubated for 1 hour at 4oC with gentle rocking. Finally, 50 µl of 2X SDS sample buffer
containing %-mercaptoethanol was added to the resin and mixture was heated at 100oC for
5 min. Samples were analyzed by WB. These experiments were repeated two times.
Retrovirus based RNAi: Slit2 shRNA lentiviral particles and control lentiviral particles
were procured from Santa Cruz biotechnology. These lentiviral particles contain 3-5
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expression constructs each encoding Slit2 specific shRNA while control lentiviral
particles encode scrambled sequences. The knockdown of Slit2 in MKT cells was
performed using the manufacturer’s protocol. Briefly, cells were transfected when they
were 50% confluent. Polybrene was added at a final concentration 5 µg/ml and Slit2
shRNA/ control lentiviral particles (ranging from 1 x 105- 5 x 105) were added to cells.
Medium was changed after 12 hrs and cells were analyzed by QPCR for Slit2 knockdown
over 2-4 days after transduction. For in vivo experiments in HSV infected mice, 1 x 105
Slit2 shRNA/control lentiviral particles were inoculated sub-conjunctivally starting at day
1 with additional doses on alternate days until day 11 and mice were monitored for the
progression of angiogenesis and SK.
Statistics: The statistical significance for SK lesion severity and angiogenesis between
two groups was determined using unpaired two-tailed student's t test. One way ANOVA
with Bonferroni’s post hoc test was used to calculate the level of significance for some
experiments. P ( 0.001 (***), P ( 0.01 (**), P ( 0.05 (*) were considered as significant.
All experiments were repeated at least two times and results are expressed as means
±SEM. For all statistical analysis, GraphPad Prism software was used.

Results
Expression of Robo4 and Slit2 after HSV infection
The pattern of expression of Robo4 and Slit2 gene and protein expression was measured
at various time points after HSV infection focusing on time points when
neovascularization was prominent and SK lesions clinically apparent. Thus, our aim was
to find evidence for a possible role of the Robo4/Slit2 interaction in constraining VEGF
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driven angiogenesis and vascular permeability. Corneas were collected at different times
post HSV infection, dissected free of normal limbal blood vessels and samples processed
either to collect vascular endothelial cells for phenotyping, or to prepare corneal RNA
samples to quantify Robo4 and Slit2 mRNA levels by quantitative PCR (QPCR). As
shown in fig 2.1A, naïve avascular corneal samples do express Robo4 mRNA (likely
produced by corneal epithelial cells) but Slit2 mRNA was barely detectable. The fact that
naïve corneas express Robo4 and Slit2, was also demonstrable by western blotting (fig
2.1B&C) and the positive controls for Robo4 and Slit2 were kept kidney and brain due to
the expression pattern of these molecules reported previously (23, 24). Changes in the
levels of Robo4 mRNAs (probably from blood vessel endothelial cells) occurred as early
as day 2 after HSV infection, and levels peaked during the clinical phase (day 7-day 14)
reflecting the appearance of neovascularization in the infected eye (fig 2.1D). However
Slit2 expression levels did not change significantly over the course of events (fig 2.1E).
By day 2, mRNA levels for Robo4 were increased by 28 fold but Slit2 only by 2.9 fold.
At the time of overt neovascularization, on day 9 post infection, Robo4 mRNA was
elevated by 51 fold, but Slit2 mRNA only 3.6 fold (fig 2.1D&E). Corneal extracts were
also analyzed for Robo4 and Slit2 proteins by western blotting on day 9. Compared to
controls, the elevated expression of Robo4 was evident with little change in Slit2 levels
(fig 2.1F).
Cells isolated from infected corneas at different times post infection were sorted
for CD31+ cells (a marker for vascular endothelial cells) and the expression of Robo4
was measured on such cells (fig 2.2A). Firstly, we could show that the percentage of
CD31+ cells that expressed Robo4 protein changed with time. Thus, at the earliest time
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point (day 1) 23.8% of cells were Robo4 positive, whereas at a later time (day 11) the
expression increased to 59.2% average. Secondly, we also compared the numbers of
Robo4+ CD31+ cells at different time points. Maximal numbers of Robo4+ CD31+ cells
were evident in samples collected at day 11 and day14 p.i (fig 2.2B). At this time point,
levels of Slit2 protein were minimal and, as already mentioned, mRNA levels were also
low in comparison to Robo4. We also attempted to sort endothelial cells from naïve
uninfected and day 11 p.i. corneas (fig 2.2C&D). Accordingly, we could not sort any
endothelial cells from naïve corneas but large numbers of endothelial cells were sorted
from day 11 p.i. corneas (fig 2.2C&D). These sorted endothelial cells from day 11 p.i.
corneas revealed the presence of Robo4 by WB (fig 2.2E). Additionally, the fact that
blood vessel endothelial cells during SK expressed Robo4 was also demonstrable by
confocal microscopy. Eyes taken from day 11 time point and subjected to confocal
microscopy revealed endothelial cells with Robo4 receptors (fig 2.2F-H). Thus, taken
together, our results could mean that although Robo4 is abundantly expressed by the new
blood vessels that result from HSV infection, there may be an inadequacy of the ligand
Slit2 to trigger an effective anti angiogenic response.
Endogenous Slit2 is dispensable during SK.
Additional experiments were performed to determine if the inhibition of Slit2 production
in HSV infected animals had any effect on the extent of the ocular angiogenesis. To
inhibit Slit2 expression, a lentiviral vector was used that expressed Slit2 shRNAs. Initial
experiments in vitro using a MKT cell line expressing Slit2 (fig 2.3A) were performed to
assess the efficacy of the lentivial knockdown system. The MKT cell line was transduced
with lentiviruses expressing Slit2 shRNA/scrambled sequences. Fig 2.3B demonstrates
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the average Slit2 gene expression values of two independent experiments. We could
achieve around 55% reduction in Slit2 mRNA transcripts when Slit2 shRNAs were
introduced into MKT cells compared to controls. We did not observe any Slit2
knockdown using scrambled sequences, which confirmed in vitro knockdown of Slit2
gene. In vivo experiments were done in HSV infected animals to determine if the
lentiviral vector expressing Slit2 shRNAs had any effect on the extent of angiogenesis.
The subconjunctival delivery (25) of lentiviruses encoding Slit2 shRNAs was started
from day 1 post HSV infection with additional administrations on alternate days (fig
2.3C). Corneas collected at day 9 revealed diminished Slit2 mRNA and protein compared
to controls (fig 2.3D&E) suggesting a reduction in Slit2 mRNA and protein in vivo after
lentiviral Slit2 shRNA administrations. However, when lentiviruses expressing Slit2
shRNA treatment was further continued in another group of mice until day 11 and
animals were observed at the end of the experiment (day 15) (fig 3F), no increase in
angiogenesis or SK lesion severity was observed (fig 2.3G&H). These experiments were
repeated three times, and the results suggest that endogenous Slit2 is dispensable during
SK (due to low amounts).
Provision of recombinant Slit2 diminishes angiogenesis and HSK.
These experiments were carried out to observe the effect of subconjuctival Slit2 protein
administration on HSV-1 induced angiogenesis. As shown in fig 2.4A, sub-conjunctival
administration of Slit2 protein (starting from day 2 p.i. with additional doses on alternate
days up to day 12) with different doses was done in mice and animals were examined at
the end time of the experiment (day 15). This resulted in a dose dependent inhibition of
angiogenesis with peak reduction achieved at the maximum dose of 1 &g Slit2 protein
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when mice were examined at day 15 time point (fig 2.4B). Thus, preventive
administration of Slit2 resulted in reduction in SK and angiogenesis scores (fig 2.4C-E).
The eyes from the Slit2 treated group revealed reduction in visible angiogenesis
compared to the mock treated group (figure 2.8A-C). The frequency and numbers of
CD31+ endothelial cells (fig 2.4F&G), CD4+ T cells (fig 4H&I) and neutrophils (fig
2.4J&K) were reduced in mice receiving Slit2 protein compared to mock treated animals.
Curiously, even though the treatment of mice with Slit2 protein was delayed up to day 7
post HSV-1 infection (with additional doses on alternate day until day 13), this treatment
modality also resulted in diminished angiogenesis and SK lesion severity (day 15) (fig
2.5A-C). Additionally, there was a reduction in the frequency and numbers of CD31+
endothelial cells (fig 2.5D&E), CD4+ T cells (fig 2.5F&G) and neutrophils (fig 2.5H&I)
and in the Slit2 treated group. Additionally, when levels of various cytokines (IL1b,
IFN", IL6 & Nos2) and chemokine’s (Cxcl1 & Cxcl2) were examined in Slit2/mock
treated group, a reduction in the levels of different cytokines and chemokines was evident
in Slit2 treated mice compared to infected controls at both day 11 and day 15 post
infection (figure 2.8D&E). Taken together, our results demonstrate that Slit2 protein
driven activation of endothelial Robo4 receptors can serve to modulate the extent of
angiogenesis and subsequent immunopathology that occurs following HSV infection.
Possible mechanism by which Slit2 exerts anti angiogenesis
Blockade of Arf 6 and Rac 1 activity during HSK by Slit2 treatment
Recent reports show that Slit2 inhibits angiogenesis by blockade of Arf 6 (19). GTPase
activation assays for Arf 6 and Rac 1 were performed to see whether exogenously
delivered Slit2 protein causes similar effects in an infectious disease setting. Mice
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infected with ocular HSV-1 were provided with 1&g Slit2 protein subconjuctivly starting
from day 2 with additional doses at day 4, day 6, day 8 and day 10. Active Arf 6 and Rac
1 were pulled down from 6 corneas collected from each group at day 11 post infection
(fig 2.6A). These were subjected to western blotting to determine levels of active Arf 6
and Rac 1. As shown in fig 6B&C, total Arf 6 levels were similar in all groups, but there
was an increase in GTP-Arf 6 in the case of mock treated animals compared to uninfected
controls. In contrast, a reduction in GTP-Arf 6 in the Slit2 treatment group was observed
indicating that Slit2 treatment resulted in the blockade of Arf 6 activity. Similar results
were obtained in analyses from GTP-Rac 1 activation assays. There was an increase in
GTP-Rac 1 in the mock treatment group over uninfected control animals but levels of
GTP-Rac 1 were undetectable in the Slit2 treated group (fig 2.6D&E). Total Rac 1
activity was similar in these groups. The above experiments were repeated two times.
Additionally, the blood vessel endothelial cells (CD 31+) were sorted from mock/Slit2
treated corneas at day 11 post infection (purity up to the extent of 85-90% was achieved)
and active Arf 6 and Rac 1 were pooled down from the endothelial cells of the respective
groups. As shown in figure 2.9A-E, levels of active Arf 6 and Rac 1 were lower in
endothelial cells taken from Slit2 treated mice compared to mock while total Arf 6 and
Rac 1 levels were similar in both groups. These experiments were repeated two times.
These results indicate that the provision of excess Slit2 to HSV-1 infected mice reduces
angiogenic Arf 6 and Rac 1 activity in the corneas.
Slit2 may reduce anti apoptotic and cell cycle signal molecules in blood vessel
endothelial cells
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The observed reduced numbers and frequency of blood vessel endothelial cells in Slit2
treated animals prompted us to investigate whether Slit2 treatments induced apoptosis of
endothelial cells in vivo. To evaluate the situation in HSV infected ocular disease,
infected mice were treated with 1 &g Slit2/ mock starting from day 2 up to day 10 on
every alternate day and corneas collected at day 11 p.i were subjected to analysis (fig
2.7A). The blood vessel endothelial cells (CD 31+) were sorted from mock/Slit2 treated
corneas at day 11 (purity up to the extent of 90% was achieved) and analyzed for the
expression of anti apoptotic Bcl-xL and cell cycle signal molecule Cyclin D1 by western
blotting. As shown in fig 2.7B-E, levels of Bcl-xL and Cyclin D1 were down regulated in
endothelial cells isolated from Slit2 treated mice compared to the mock treated group.
These experiments were repeated two times. Additionally, these sorted blood vessel
endothelial from both groups were subjected to WB and analyzed for the expression of
active caspase 3 (indicating apoptosis). As shown in figure 2.10A-C, the level of caspase
3 was higher in endothelial cells taken from Slit2 treated mice (indicating more
apoptosis) compared to the mock treated group. The above experiments were repeated
two times. The results of these experiments indicate that Slit2 treatments reduce anti
apoptotic and cell cycle signal molecules while increase caspase 3 in blood vessel
endothelial cells during SK.

Discussion
HSV ocular infection results in neovascularization of the normally avascular cornea. This
represents a key event in the pathogenesis of a chronic inflammatory reaction in the eye
(5-7, 9). In consequence, understanding how to control pathological angiogenesis is
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relevant since it could result in improved therapy of a lesion, stromal keratitis that is an
important cause of human blindness. In the present report, we have evaluated if a host
feedback anti-angiogenesis mechanism, namely the stimulation by Slit2 ligand of Robo4
receptors on vascular endothelial cells, is operative in an infectious disease situation and
to determine if manipulating the feedback system could represent a useful approach to
constrain lesion severity. We demonstrate that Robo4 receptors are up regulated
following HSV infection and that the majority of new blood vessel endothelial cells
express Robo4. However, the expression levels of the Robo4 ligand, Slit2 were not
significantly increased during the disease process. Moreover, the inhibition of Slit2 gene
expression using lentiviral shRNAs had no effect on the extent of pathological
angiogenesis. In contrast, providing additional Slit2 protein by subconjunctival
administration resulted in significantly reduced angiogenesis. Mechanistically, the
Slit2/Robo4 interaction was shown to block the downstream VEGF signaling molecules
Arf 6 and Rac 1 and reduced the anti-apoptotic molecule Bcl-xL in blood vessel
endothelial cells. Our results indicate that augmenting the host Robo4/Slit2 antiangiogenesis system could provide a useful therapeutic approach to control pathological
angiogenesis associated with HSV induced stromal keratitis.
Stromal keratitis remains a significant cause of vision impairment and new forms of
therapy are needed. Controlling the extent of neovascularization, a key event in SK
pathogenesis, represents a logical target for therapy. In animal models of SK, we and
others have shown that reducing angiogenesis, as can be achieved by inhibiting the
expression of angiogenic factors, results in milder lesions (6, 15, 16, 26). Similarly,
angiogenesis is damaging to the retina and one treatment finding favor in the clinic is to
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use the anti VEGF monoclonal antibody, bevacizumab (27, 28). Recently, it became
apparent that the host itself has one or more systems that counteract the stimuli for new
blood vessel development and malfunction. We chose to investigate the Slit2/Robo4
system since this anti-angiogenic feedback mechanism was shown recently to influence
vascular disease induced by trauma to the retina (18, 19). Moreover, both Slit2 and
Robo4 can be artificially induced in the cornea by implants containing the angiogenic
factor FGF (29). However, it was not known if the Slit2/Robo4 feedback mechanism had
any regulatory effect in any natural infectious disease models where typically, as in SK,
multiple angiogenic factors are involved in driving the pathological angiogenesis.
Our results clearly show that the Robo4 up regulation becomes evident early after
infection. We could show that the majority of the endothelial cells recovered from the
neovascularized corneas expressed Robo4 receptors. Accordingly, the Robo4 mediated
anti-angiogenesis system was poised to perform its regulatory function. Nevertheless, we
advocate that this potential regulatory event may be inadequate during SK lesion
pathogenesis since the ligand for Robo4, Slit2 was in limited supply. The reasons for this
were not established, but they could relate to an inhibitory effect of virus on Slit2 gene
expression which may be derived from corneal epithelial cells (29-32). This issue is
currently under investigation. Following infection, a modestly increased expression of
Slit2 did occur but this was considered as insignificant. Moreover, when Slit2 gene
expression was reduced in the cornea, as was achieved using a lentivirus system that
expressed shRNA for Slit2, an anticipated increase in the extent of pathological
angiogenesis (20) was not observed. Accordingly, we must conclude that during the
pathogenesis of HSV ocular lesions, the host Slit2/Robo4 anti-angiogenesis feedback
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mechanism fails to influence the outcome of events. Nevertheless, we could also show
that the anti-angiogenic system could be activated and play a modulatory effect on the
virus induced angiogenesis. This was done by providing an additional supply of Slit2
protein locally to the eye by subconjunctival injection. This procedure, which could be
started as late as day 7 p.i resulted in significantly reduced angiogenesis and SK lesion
severity compared to untreated controls. Additionally, we could observe a reduction in
levels of various cytokines and chemokines in the corneas of Slit2 treated mice which is
in line with recent findings of others (21). Our results support the observations of Jones et
al (18, 19) using a non infectious vascular disease model in the retina that intravitreal
administration of additional Slit2 protein can diminish vascular disease.
Previous reports indicate that a number of biochemical events could explain the
mechanisms by which Slit2 exerts its anti-angiogenic effect (18, 19, 33). These include
activation of Robo4 receptors, which recruits paxillin and GIT 1 that in turn blocks
angiogenic Arf 6 (VEGF downstream signaling) activity (18, 19). However, others
suggest that Slit2 accelerates apoptosis in tumor systems by reducing the expression of
the anti-apoptotic molecule Bcl-xL as well as diminishing cell cycle signal molecules
such as Cyclin D 1 (33). Our results demonstrate that the Slit2 treatment in HSV infected
mice resulted in significant reduction in Arf 6 and Rac 1 activity in corneas but the
treatment modality also led to reduction in anti apoptotic Bcl-xL and cell cycle signal
molecule Cyclin D1 while increased caspase 3 levels in blood vessel endothelial cells of
Slit2 treated mice. Future studies are under investigation to determine whether blockade
of downstream signaling molecules of VEGF such as Arf 6 or increasing cell cycle
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inhibitors in blood vessel endothelial cells will lead to modulation of angiogenesis and
SK.
In conclusion, we have demonstrated that enhancing natural Slit2/Robo4 anti-angiogenic
host feedback mechanism reduces virus induced angiogenesis and subsequent
immunopathology. Here we show that the majority of the blood vessel endothelial cells
recovered from the neovascularized corneas during SK expressed the Robo4 receptors.
Nevertheless, the ligand Slit2, was found to be minimal leading to ineffectiveness of this
natural

feedback

mechanism

to

control

angiogenesis

during

this

blinding

immunopathology. Thus, the provision of additional amount of Slit2 protein led to
significant reduction in angiogenesis and diminished immunopathology during SK.
Accordingly, we advocate that manipulating the function of the host feedback mechanism
holds promise as a potential approach for therapy of SK.
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Figure 2.1. Expression of Robo4 and Slit2 after HSV infection. WT mice were
sacrificed and 6 corneas were collected and pooled for mRNA analysis by RTPCR and
for protein analysis by WB. (A) Agarose gel analysis of Robo4 (394 bp)(Lane 4) and
Slit2 (465 bp) (Lane 6) transcripts from naive corneas (Pooled n=6 corneas). Lane MMarker, lane 2 is beta actin (325 bp). Lane 1, 3, and 5 are RT negative control for beta
actin, Robo4 and Slit2 while lane 7 is negative control (water). Data are representative of
three independent experiments. Reducing Western blot (WB) analysis of Robo4 (B) and
Slit2 (C) protein in naïve corneas is shown. The kidney and brain were used as positive
controls for Robo4 and Slit2 respectively. These experiments were repeated three times.
WT mice were infected with HSV-1 RE in one eye and 6 corneas were collected and

"

:="

pooled for analysis ether by QPCR or by WB. (D) Kinetic analysis of the expression of
Robo4 mRNA levels shows peaks around day 7-day 14 p.i. Data are mean ± SEM
(Pooled n=6 mice). (E) Quantification of Slit2 mRNA at different time points post HSV
infection. Data are mean ± SEM (Pooled n=6 mice). (F) Reducing WB analysis of
corneal samples from naive uninfected and day 9 p.i. reveals increase in Robo4 protein in
infected corneas while slight change in Slit2 protein at day 9 p.i (Pooled n=6 mice).
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Figure 2.2. Robo4+ blood vessel endothelial cells in corneas after HSV infection. WT
mice were infected with HSV-1 RE in one eye and 6 corneas were collected and pooled
for analysis by flow cytometry. (A) Representative FACS plots from each time point
show the percentage of Robo4+ blood vessel endothelial cells. Isotype controls are shown
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as faint grey lines. Data are representative of three independent experiments. (B) Total
number of Robo4+ blood vessel endothelial cells per cornea at each time point post HSV1 infection reveals an increase in Robo4+ endothelial cells over time during SK with
maximum number of cells observed at day 11 and day 14 p.i. Data are mean ± SEM
(Pooled n=6 mice). These experiments were repeated three times. The sorting of CD31+
endothelial cells from naive uninfected mice (C) and day 11 p.i. corneas (D) is shown
which reveals absence of endothelial cells in naive corneas while large number of
endothelial cells were present in day 11 p.i. corneas. These sorted endothelial cells from
HSV infected corneas were further subjected to WB to detect the presence of Robo4 (E)
while kidney was used as a positive control for Robo4 detection. Representative
immunofluorescence staining of endothelial cells sorted from day 11 p.i. corneas for
blood vessel endothelial cells (green) (F), Robo4 (red) (G) and merge (Robo4+
endothelial cells) (H) reveals the presence of Robo4 on the blood vessel endothelial cells
during SK. Single endothelial cell is shown. Image is the representative of two
independent experiments. Original magnification x60.
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Figure 2.3. Slit2 is dispensable during SK. (A) MKT cells expressing Slit2 mRNA
transcripts. Agarose gel analysis of Slit2 (465 bp) (Lane 3) transcripts in MKT cells. Lane
M-Marker, lane 1 is beta actin (325 bp). Lane 2 and lane 4 are RT negative control for
beta actin and Slit2 respectively. Image is representative of three independent
experiments. (B) Knockdown of Slit2 in MKT cells. Lentiviruses expressing Slit2
shRNA/scrambled sequences were introduced into MKT cells and quantification of Slit2
mRNA was carried out to evaluate Slit2 knockdown. One way ANOVA with
Bonferroni’s post hoc test was used to calculate the level of significance. **P ( 0.01.
These experiments were repeated three times. WT mice were infected with HSV-1 RE in
one eye and 6 corneas were collected and pooled for analysis by QPCR or WB. (C)
Lentiviruses
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subconjunctively in HSV infected mice as indicated. (D) Quantification of Slit2 mRNA
from corneas isolated from different groups revealed knockdown of Slit2 mRNA in Slit2
shRNA treatment group (Pooled n=6 mice/group). The level of significance was
determined by student’s t test (unpaired). *P ( 0.05. These experiments were repeated
three times. (E) Reducing WB for Slit2 protein after treatment of HSV infected mice with
Slit2 shRNA/scrambled sequences (Pooled n=6 mice/group). WT mice were infected
with HSV-1 RE in one eye and mice were monitored for the development of angiogenesis
and SK up to day 15. (F) Lentiviruses expressing Slit2 shRNA/scrambled sequences were
injected subconjunctively in HSV infected mice as indicated. HSK scores (G) and
angiogenesis scores (H) at day 15 after the treatment of mice with either lentiviruses
expressing Slit2 shRNAs/scrambled sequences. One way ANOVA with Bonferroni’s post
hoc test was used to calculate the level of significance. No statistical significant
differences among groups were observed. These experiments were repeated three times."
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Figure 2.4. Preventive administration of recombinant Slit2 protein diminishes
angiogenesis and HSK. WT mice were infected with HSV-1 RE in one eye and 6
corneas were collected and pooled for analysis by flow cytometry. (A) The Slit2/mock
treatment was given to HSV infected mice as shown. (B) The dose dependent inhibition
of angiogenesis scores after Slit2 treatment with maximum reduction in angiogenesis at 1
&g Slit2 protein dose. These experiments were repeated two times. The Slit2 treatment
regimen (C) resulted in reduction in HSK (D) and angiogenesis scores (E) in HSV
infected animals. The frequency and total cell number per cornea for endothelial cells
(CD31+ cells) (F & G), CD4+ T cells (H & I) and neutrophils (Gr1+, CD11b+ cells) (J &
K) showed significant reduction in frequency and total cell number per cornea after
preventive Slit2 treatment (Pooled n=6 mice/group). The level of significance was
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determined by student’s t test (unpaired). **P ( 0.01, *P ( 0.05. These experiments were
repeated two times.
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Figure 2.6. Blockade of Arf 6 and Rac 1 activity after Slit2 treatment. WT mice were
infected with HSV-1 RE in one eye and 6 corneas were collected and pooled for analysis by
GTPase activation assays. (A) WT mice infected with HSV were treated with Slit2/mock as
shown. The corneas collected at day 11 p.i. after Slit2/mock treatment were subjected to Arf 6
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the respective groups (Pooled n=6 mice/group). The results of two independent experiments are
shown.
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ocularly infected with 104 PFU HSV-1 RE in one eye and monitored for the development of
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HSV infected mice. Representative eye photographs from (B) Slit2/mock (C) treated group at
day 15 post HSV infection are shown. These experiments were repeated two times. The
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chemokine’s (Cxcl1 & Cxcl2) in Slit2 (white bars)/mock (black bars) treated group at day 11 (D)
and day 15 (E) p.i. are shown (Pooled n=6 mice/group). These experiments were repeated two
times.
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Figure 2.9. Slit2 inhibits Arf 6 and Rac 1 activity in endothelial cells during HSK. WT mice
were infected with HSV-1 RE in one eye and 12 corneas were collected and pooled for analysis
by WB. The HSV infected mice were treated with Slit2/mock as shown (A) and CD 31+ cells
were sorted from mock and Slit2 treated mice corneas. These sorted CD 31+ cells from
respective groups were subjected to Arf 6 (B&C) and Rac 1 (D&E) pull down followed by
reducing WB analysis for Arf 6 and Rac 1 of the respective groups (Pooled n=12 mice/group).
The results of two independent experiments are shown.

"

;="

!!!!!!A
!!!!!!!!!!!!

Slit2 (1µg) or Mock
!
0

2

4

6

8

10

11 days p.i.

Sorting of CD 31+ cells
from corneas

HSV infection

!!!!!!B
!!!!!!!!!!!!

!!!!!!C
!!!!!!!!!!!!
Mock

Slit2

Mock

Slit2

Caspase 3

!17 kDa
!!!!!!!!!!!!!!!!!!!!

Caspase 3

! actin

!!43 kDa
!!!!!!!!!!!!!!!!!!!!

! actin
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Part III

Role of microRNA-132 in angiogenesis after ocular
infection with herpes simplex virus
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Research described in this chapter is reproduced from a publication accepted in American
journal of pathology by Mulik S, Xu J, Reddy PB, Rajasagi NK, Gimenez F, Sharma S,
Lu PY and Rouse BT.
Mulik S, Xu J, Reddy PB, Rajasagi NK, Gimenez F, Sharma S, Lu PY, Rouse BT. Role
of microRNA-132 in angiogenesis after ocular infection with herpes simplex virus. Am J
Pathol. 2012 Aug; 181(2): 525-34. Reprinted from Am J Pathol 2012, 181:525-534 with
permission from the American Society for Investigative Pathology.

Abstract
MicroRNAs (miRNAs) are small regulatory molecules that control diverse
biological processes that include angiogenesis. Herpes simplex virus (HSV) infection of
the

eye

may

result

in

corneal

neovascularization

(CV)

during

blinding

immunopathological lesion stromal keratitis (SK). miR-132 is a highly conserved
miRNA which is induced in endothelial cells in response to growth factors. In this study,
we show that miR-132 expression was up regulated (10-20 fold) after ocular infection
with HSV an event that involved VEGF-A and IL-17 production. Thus, blocking VEGFA activity using soluble VEGF receptor 1 resulted in significantly lower corneal miR-132
levels following HSV infection. Additionally, IL-17RKO mice revealed low levels of
corneal miR-132 levels after HSV infection. In vivo silencing of miR-132 by the
provision of anti miR-132 (antagomir-132) nanoparticles to HSV infected mice led to
reduced CV and diminished SK lesions. The anti-angiogenic effect of antagomir-132 was
reflected by reduction in angiogenic Ras activity in corneal CD31 enriched cells
(presumably blood vessel endothelial cells) during SK. To our knowledge, this is one of
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the first reports of miRNA involvement in an infectious ocular disease. Manipulating
miRNA expression holds promise as a therapeutic approach to control an ocular lesion
that is an important cause of human blindness.

Introduction
Herpes simplex virus (HSV) causes a chronic immuno-inflammatory response in
the eye that is a significant cause of human blindness 1. The blinding lesion represents a T
cell orchestrated reaction in the corneal stroma set off by the infection 2. These stromal
keratitis (SK) lesions involve cellular and cytokine events that resemble those seen in
some autoimmune diseases and control measures found effective in autoimmunity often
similarly act to control SK. One major feature of SK that is not usually a prominent part
of an autoimmune lesion is pathological angiogenesis 3. Thus the corneal site where SK
occurs is normally an avascular tissue, which is a requisite for normal vision. Once
corneal neovascularization (CV) has occurred, inflammatory cells can easily gain access
to the eye, vision is impaired and blood vessels, once formed, are difficult to remove 2.
Hence, a major objective of therapies to control SK and several other ocular lesions is to
prevent or control the extent of neovascularization 4. Several approaches have been
evaluated to achieve this objective but none have proven to be fully effective and
alternative strategies are needed. Conceivably, controlling the expression of one or more
species of microRNAs (miRNAs) is one such strategy. Thus several recent studies have
indicated that miRNAs are exploitable gene regulators and many of them may be
dysregulated during tissue damaging inflammatory reactions as well as during
pathological angiogenesis 5, 6. Of particular interest miR-132 was shown to act as a switch
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to activate embryonic human vascular endothelial cells to undergo vasculogenesis 7. The
miR-132 was also upregulated during pathological angiogenesis in a tumor model and
inhibiting miR-132 by antagomir nanoparticles was inhibitory to tumor angiogenesis 7.
To date the role for miRNA in tissue damage and angiogenesis caused by an
infectious agent is poorly understood. Some recent reports, however, have indicated that
miRNA encoded by virus can play a role in the expression of latency 8, the induction of
tumors

9

and may be involved in human cytomegalovirus immune evasion

10

. We show

herein that targeting miR-132 represents a potentially valuable approach for the control of
the CV that occurs during SK. Accordingly, miR-132 expression is upregulated following
infection and blockade of VEGF-A activity resulted in significantly lower corneal miR132 levels. Of particular interest, IL-17RKO mice produced less miR-132 in corneas after
infection. Additionally, administration of antagomir-132 nanoparticles led to diminished
angiogenic Ras activity that was reflected by significantly reduced angiogenesis and
diminished SK lesions. The results of these studies indicate that manipulating miRNAs,
as shown here by targeting miR-132, might provide an additional avenue for the control
of an important cause of vision loss.

Materials and methods
Mice: Female 6-8 wks old C57 BL/6 mice were purchased from Harlan Sprague Dawley
Inc. (Indianapolis, Indiana, USA). IL-17RKO mice on C57BL/6 background were
obtained from Amgen (Thousand Oaks, CA). The animals were housed in American
Association of Laboratory Animal Care-approved facilities at the University of
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Tennessee Knoxville. All investigations followed guidelines of the institutional animal
care and use committee.
Virus: HSV-1 strain RE Tumpey was propagated in Vero cell monolayers (ATCC no:
CCL81). Virus was grown in Vero cell monolayers (American Type Culture Collection,
Manassas, VA), titrated, and stored in aliquots at –80˚C until used.
Corneal HSV-1 infection and scoring: Corneal infections of mice were performed
under deep anesthesia. The mice were lightly scarified on their corneas with a 27-gauge
needle, and a 3 &l drop containing 104 PFU of HSV-1 RE Tumpey was applied to one
eye. The development of SK lesion severity and angiogenesis in the eyes of mice was
examined by slit-lamp biomicroscopy (Kowa Company, Nagoya, Japan). The scoring
system used was as follows: 0, normal cornea; 1, mild corneal haze; 2, moderate corneal
opacity; 3, severe corneal opacity; 4, opaque cornea and ulcer; 5, corneal rupture. The
severity of angiogenesis was recorded as described previously

11

. According to this

system, a grade of 4 for a given quadrant of the circle represents a centripetal growth of
1.5 cm towards the corneal center. The score of the four quadrants of the eye were then
summed to derive the neo vessel index (range 0-16) for each eye at a given time point.
Sub-conjunctival injections: Sub-conjunctival injections were performed as reported
previously

12

. Briefly, these injections were carried out using a 2-cm, 32-gauge needle

and syringe (Hamilton, Reno, NV) to penetrate the perivascular region of conjunctiva and
appropriate amount of soluble VEGF receptor 1 protein/isotype or scrambled
sequences/antagomir-132 nanoparticles was administered into sub-conjunctival space.
Antagomir sequences: Anti miR-132 and scrambled sequences were procured from
Ambion and used as reported previously 7.
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Nanoparticle preparation: Optimized histidine-lysine polymers (HKP) have been
applied for siRNA deliveries in vitro and in vivo

13

. One HK polymer species, H3K4b,

having a Lysine backbone with four branches containing multiple repeats of histidine and
lysine, was used for packaging siRNAs against miR-132 or scrambled sequences with a
nanoparticle to sequences ratio of 4:1 by mass. The nanoparticles (average size of 150 nm
in diameter) were self-assembled and these HKP-siRNA nanoparticles were used in mice.
Mice treatment with antagomir-132 nanoparticles: Mice ocularly infected with HSV1 RE Tumpey were separated into two groups. Antagomir-132 nanoparticle treatment
was begun at day 2 with additional doses on alternate days until day 13 post infection. In
another group of experiments, the antagomir-132 treatment was started at day 7 or day 10
with additional doses on alternate days until day 13 post infection. Control group
received nanoparticles containing scrambled sequences sub-conjunctively with the same
regimen for respective experiments. These animals were carefully followed for the
progression of angiogenesis and SK development. All experiments were repeated two
times.
Purification of CD31 enriched cells: Purification of CD31 enriched cells (presumably
endothelial cells) from HSV infected corneas was carried out as described previously 14.
Briefly, the excised corneas were pooled and digested with 60 U/ml Liberase for 35
minutes at 370C in a humidified atmosphere of 5% CO2. Single cell suspension was
prepared and stained with anti CD31-FITC for 30 minutes on ice and FITC+ CD31+ cells
were sorted using a FACS sorter. Purity to an extent of 80-90% was achieved. These
sorted CD31 enriched cells were used for pull down assays.
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Flow Cytometry: Corneal single cell suspensions were prepared following Liberase
digestion of corneas. These corneal cell suspensions were then stained for different cell
surface molecules. Briefly, cell suspensions were incubated with CD45-allophycocyanin
(30-F11), CD11b-PerCP (M1/79), Gr1-PE (1A8), CD 4-allophycocyanin (RM4.5) and
CD31-FITC (BD Biosciences) for 30 minutes on ice. Thereafter, cells were washed three
times and resuspended in 1% para-formaldehyde. Stained samples were acquired with a
FACS Calibur (BD Biosciences) and the data were analyzed using the FlowJo software.
Quantitative PCR (QPCR): Total mRNA was isolated from corneal cells using TRIzol
LS reagent (Invitrogen, Carlsbad, California, USA). The cDNA prepared using 1 µg of
RNA was used for subsequent analysis. QPCR was done using SYBR Green PCR Master
Mix (Applied Biosystem, Foster City, CA, USA) with iQ5 real-time PCR detection
system (Bio Rad, Hercules, CA, USA). The expression levels of the target genes were
normalized to %-actin with 'Ct method and relative quantification between control and
infected mice was performed using the 2-''Ct formula. The primers used are as follows.
RasGAPF 5’GAGAAGAAGATCCACACGAAGG3’

and

RasGAPR 5’CTCCAGGAGTATTATCTGAGGG3’,

%-actinF 5’CTACCTCATGAAGATCCTGACC3’

and %-actinR 5’GTCTAGAGCAACATAGCACAGC3’.

TaqMan miRNA Quantitative PCR (TaqMan QPCR): The miRNAs were extracted
from HSV infected mice corneas using mirVana™ miRNA Isolation Kit (Ambion,
Austin, TX, USA). These extracted miRNAs were converted to cDNAs using TaqMan
MicroRNA Reverse Transcription Kit (Applied Biosystems, USA) and primers for miR132 and miR-133a. TaqMan MicroRNA Assays (Applied Biosystems, USA) for miR-132
and miR-133a were used to quantify these microRNAs using real-time PCR detection
system (Applied Biosystems, USA). Data were normalized to the internal control small
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nucleolar RNA 202. miR-133a (which is generally expressed in muscle cells) was used as
a negative control for miRNA quantification from corneas 15.
Neutrophil depletion with mAb: Depletion of neutrophils during SK was performed as
described previously

16, 17

. Mice ocularly infected with HSV-1 RE Tumpey were

separated into two groups. One group of animals was administered with 200 µg of anti
Ly6G mAb (1A8; BioXcell, West Lebanon, NH) intraperitoneally on alternate days
starting from day 7 until day 13 post infection. Experiments were terminated on day 14 pi
and corneal samples were collected for further analysis. Animals in control group were
given isotype control (IgG2b) Ab (LTF-2; BioXcell) following the same regimen. These
experiments were repeated two times.
Western blot analysis: The corneal cells were lysed and total protein in the supernatants
was quantified using BCA protein assay kit (Thermo scientific, Waltman, MA). Samples
were denatured in Laemmli buffer and resolved by SDS-PAGE and proteins were
transferred onto a PVDF membrane. The membrane was blocked with 5% BSA in Trisbuffered saline with Tween 20 at 40C overnight and subjected to incubation with specific
primary

and

secondary

antibodies.

Proteins

bands

were

visualized

using

chemiluminiscent HRP substrate (Millipore, Billerica, MA). After keeping in stripping
buffer for 10 minutes, the membrane was re-probed using anti %-actin antibody. The
antibodies used were as follows: mouse Ras (Thermo scientific, USA), anti %-actin (C4),
anti Ras-GAP (B4F8), mouse anti VEGF-A (EE02), goat anti mouse IgG-HRP and
donkey anti goat IgG-HRP (All these antibodies were procured from Santa Cruz
biotechnology).
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Ras activation assay: Ras activation assays were carried out using Active Ras pull down
and detection kit (Thermo scientific) according to manufacturer’s protocol. Briefly, resin
slurry was added to the spin cup in a collection tube and 100 µg GST GGA3-PBD fusion
protein with 800 µg total protein (corneal cell lysate) was added to this slurry. This was
incubated at 4oC for 1 hour and finally 50 µl reducing sample buffer was added and GTPRas was pulled down and subsequently analyzed by WB. These experiments were
repeated two times.
Viral plaque assay: Virus titers were measured in the eye swabs taken from HSV
infected mice using plaque assays as described previously by others 18.
Statistics: The statistical significance for SK lesion severity and angiogenesis between
two groups was determined using unpaired two-tailed student's t test. One way ANOVA
with Bonferroni’s post hoc test was used to calculate the level of significance for some
experiments. P ( 0.001 (***), P ( 0.01 (**), P ( 0.05 (*) were considered as significant
and results are expressed as mean ±SEM. For all statistical analysis, GraphPad Prism
software was used.

Results
miR-132 is upregulated in mice corneas after ocular infection with herpes simplex
virus
To measure changes in miR-132 levels following ocular HSV infection, tissues
were collected at various times and miRNAs quantified by QPCR. Changes in the levels
of miR-132, but not control miR-133a, were evident by day 2 p.i. in infected samples
with peak expression levels evident in day 7 and day 14 p.i. samples (figure 3.1A&B).
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Uninfected scratch controls at the same time points showed no changes in the levels of
miR-132 (data not shown). These data demonstrate that miR-132 expression is elevated
at multiple time points after ocular HSV infection.
Blockade of VEGF-A activity diminishes corneal miR-132 levels during SK
The increased expression of miR-132 at time points when virus was cleared from
the eyes and CV becomes quite evident (usually by day 7 p.i) raised the issue as to the
triggers responsible for miR-132 upregulation. Since VEGF-A levels are increased
following HSV infection and remain so throughout the disease syndrome

17

, VEGF-A

was suspected to be an agonist for miR-132 up-regulation. Moreover, VEGF-A can
induce miR-132 expression in the human cell line HUVEC 7. To investigate the role for
VEGF-A, we measured the effect of VEGF-A blockade on the expression of miR-132
levels. To effect VEGF-A blockade, animals were treated after infection with 5&g VEGF
trap (soluble VEGF receptor 1) or isotype control on alternate days starting from day 2 up
to day 12 p.i. These conditions were shown previously to markedly suppress VEGF-A
protein activity and also to significantly inhibit CV 17. The corneas were collected at day
7 and day 14 p.i and miR-132 levels were compared in isotype control and VEGF trap
treated animals. When compared to uninfected scratch controls, the miR-132 levels were
elevated at day 7 p.i. in isotype treated animals. However, miR-132 in the recipients of
the VEGF trap were on average 4 fold less than in isotype treated animals (figure 3.2A).
The same pattern was evident at day 14 p.i. in mice treated with VEGF trap compared to
isotype treated animals (figure 3.2A).
In another set of experiments, neutrophils were depleted

16

during the clinical

stage of SK (figure 3.2B). Neutrophils are a source of VEGF-A and their depletion results
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in lower VEGF-A levels in corneas obtained from HSV infected mice

17

. Depletion

(using 200&g anti Ly6G antibody) was begun at day 7 p.i with additional doses on
alternate days up to day 13. Neutrophil depletion was clearly evident in spleen and
corneas of HSV infected mice treated with anti Ly6G antibody (figure 3.8A-C).
Expression levels of miR-132 were compared in corneal pools from depleted and isotype
control mice on day14 p.i. VEGF-A levels were reduced after depletion of neutrophils in
these experiments (figure 3.2C). As shown in figure 3.2D, miR-132 expression levels
were reduced by on average 3 fold in the neutrophil depleted mice compared to isotype
treated animals. Taken together the two approaches support the notion that VEGF-A
could be responsible for the upregulation of miR-132 expression during HSV induced
CV.
Diminished levels of miR-132 in IL-17RKO mice after HSV infection
Our recent observations that mice unable to respond to IL-17A showed reduced
corneal VEGF-A levels

19

led us to investigate the possible role of IL-17A on miR-132

expression after HSV infection. To this end, IL-17A receptor knockout (IL-17RKO) mice
or WT mice were infected with HSV and miR-132 levels were measured at day 2, 7 and
14 p.i while Ras-GAP levels (miR-132 target) were measured at day 7 p.i. The significant
increase in the levels of Ras-GAP was evident in IL-17RKO mice (figure 3.2E). As
shown in figure 3.2F&G, IL-17RKO mice showed reduced CV and SK lesions compared
to WT animals. Additionally, when miR-132 levels were measured in the infected
corneas at day 7 and 14 p.i, IL-17RKO mice showed two fold reduction in miR-132
levels compared to WT mice (figure 3.2H). The results from these experiments indicate
that the cytokine IL-17A is involved in miR-132 upregulation after HSV infection.
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In vivo silencing of miR-132 by antagomir-132 nanoparticles reduces angiogenic Ras
1 in corneas
Experiments were done using nanoparticles containing an antagomir for miR-132
or scrambled sequences to determine the effect of antagomir treatment on miR-132 levels
in post infection corneas. A dose of 2.5&g antagomir-132 provided significant miR-132
knock down when measured at day 7 p.i (fig 3.3A&B). Since miR-132 targets RasGAP
mRNA 7, levels of both RasGAP mRNA and protein were measured. These were
elevated in mice treated with antagomir-132 nanoparticles compared to scrambled
sequence recipients (fig 3.3C&D).
Additional experiments were performed to measure expression of active Ras 1
following in vivo knockdown in infected animals, since miR-132 promotes VEGF
signaling by influencing active Ras levels in HUVEC cells 7. Mice infected with HSV
were given 2.5&g antagomir-132, or scrambled sequences, subconjuctivaly starting from
day 2 p.i with additional doses on alternate days until day 10 p.i. Active Ras 1 was pulled
down from 6 corneas collected from each group at day 11 p.i (figure 3.4A). As shown in
figure 4B&C, total Ras 1 levels were similar in all groups, but an increase in GTP-Ras 1
was evident in animals treated with scrambled sequences compared to uninfected
controls. In contrast, a reduction in GTP-Ras 1 was observed in the antagomir-132
treatment group. Additionally, active Ras 1 pulled down from the CD31 enriched cells
(presumably blood vessel endothelial cells) sorted from scrambled sequences or
antagomir-132 treated mice corneas at day 11 p.i, revealed reduction in active Ras 1 in
antagomir-132 treated mice (figure 3.9D&E). Curiously there was no difference in
VEGF-A levels between these groups (figure 3.4D&E). Collectively, these results
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indicate that the provision of antagomir-132 to HSV-1 infected mice reduces the
angiogenic Ras 1 activity but does not affect VEGF-A levels in the corneas.
Provision of antagomir-132 nanoparticles diminishes corneal neovascularization
To evaluate the effect of inhibiting miR-132 expression on the extent of
angiogenesis induced following infection, animals were given an optimal dose
subconjunctivally of antagomir-132, or control nanoparticles, either starting treatment at
day 2 or day 7. As shown in fig 3.5A-C, treatment begun on day 2 resulted in
significantly reduced CV in the antagomir treated animals and SK severity was also
significantly reduced. Visible reduction in angiogenesis was evident in eyes of mice
treated with antagomir-132 (figure 3.9A-C). Examination of collagen digested corneas at
the termination of experiments on day 14 revealed that inflammatory cells were
significantly diminished in numbers in the antagomir-132 treated group (fig 3.5D-I). We
also measured the ocular viral titers on day 5 p.i. after administration of antagomir-132 or
scrambled sequences and slight increase in viral levels was evident in antagomir-132
treated animals (figure 3.10A&B).
In the experiments where treatment was begun on day 7 p.i. significantly
diminished angiogenesis was also evident in the antagomir-132 treated animals (figure
3.6A-C). At the end of experiments on day 14, subpools of corneal collagen digests were
analyzed by flow cytometry to enumerate the numbers of the CD31+ cells (a marker for
vascular endothelial cells) as well as Gr1+CD11b+ cells (figure 3.6D-G). Both cell
populations were significantly reduced in number in the recipients of antagomir-132
compared to those that received the scrambles sequence nanoparticles. In addition, the
infiltration of CD4+ T cells was reduced in antagomir-132 treated animals compared to
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scrambled sequence controls (figure 3.6H&I). Curiously, even when antagomir-132
treatment was started as late as day 10 p.i. (after establishment of blood vessels in eyes),
this treatment modality resulted in reduction in corneal neovascularization (figure 3.10CE) but these changes were not statistically significant. Taken together, our results
demonstrate that the silencing of miR-132 in the HSV infected eyes modulates the extent
of angiogenesis and the subsequent immunopathology that occurs following HSV
infection.

Discussion
Ocular HSV infection results in corneal neovascularization (CV) in the normally
avascular cornea. This represents a key event in the pathogenesis of a chronic
inflammatory lesion in the eye that impairs vision. In consequence, understanding how to
control pathological angiogenesis is a significant therapeutic objective. Recently, it has
become evident that the process of neovascularization in tumors is influenced by a
number of miRNAs, particularly miR-132, that act to control the response of vascular
endothelial cells to angiogenic factors such as VEGF-A. We have evaluated the role of
miR-132 in an infectious disease model involving angiogenesis that represents an
important cause of human blindness. We show that miR-132 is upregulated in the corneas
soon after infection with levels remaining elevated throughout the chronic inflammatory
reaction caused by the infection. Of notable interest, the extent of CV could be
significantly diminished by local administration to the eye of nanoparticles containing
antagomirs that blunted the miR-132 response. Furthermore, inhibition of CV could still
be achieved when the therapy was begun 7 days p.i, a time when CV was underway, the
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chronic inflammatory reaction clinically evident and replicating virus infection no longer
present in the eye. However, inhibition of CV was not complete after antagomir-132
treatment and it is possible that using additional approaches along with antagomirs might
be more successful. One critical event influenced by miR-132 was the response of
VEGFR2 expressing vascular endothelial cells to VEGF-A as was recently described by
the Cheresh group 7. MiR-132 was shown to target Ras-GAP, an endogenous inhibitor of
Ras, which when activated is responsible for causing vascular endothelial cells to
proliferate. In agreement with these observations, we could show in our study that the
administration miR-132 antagomirs diminished Ras activity in the CD31 enriched cells
(presumably blood vessel endothelial cells). Our results indicate that modulating miRNA
represents an effective approach to control CV which reflects in reducing the severity of
SK lesions caused by HSV infection. The results are summarized in figure 3.7.
MiRNAs are becoming well known as regulators of immunity and inflammation
and manipulating their expression holds promise as a therapeutic maneuver

20

. Few

studies to date have focused on the relevance of miRNA in the control of pathological
angiogenesis. However, it is becoming evident that levels of several miRNA species are
changed during tumor angiogenesis which to date have been the systems mainly
investigated. The miRNA with changed expression include miR-132, miR-20a, miR-21
and miR-106a 5. Recently, the Cheresh group drew attention to a likely major role for
miR-132 during angiogenesis since miRNA screens of embryonic vascular endothelial
cell (HUVEC) responses to VEGF-A stimulation, revealed that miR-132 expression was
the most elevated 7. Moreover, they could show that normal expression of miR-132 was
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necessary for vascular development and that preventing its upregulation was beneficial in
a tumor angiogenesis system.
Apart from effects of miR-132 on angiogenesis, the miRNA may also influence
aspects of neural function, which has been reported to occur in some other systems

21-23

.

Since the pathogenesis of HSV often involves stress related effects on a latent infection in
the nervous system, it is conceivable that regulation by miR-132 is involved in this
process. This issue merits further investigation.
In addition, rapid responses to some viruses, that include HSV, may induce miR132 24, although such responses are likely to represent innate reactions to the virus rather
than being responses to virus gene expression. In line with this LPS, a TLR-4 ligand, may
also cause the rapid expression of miR-132 in macrophages in vitro 22. In our studies, we
noted early upregulation (by 48 hr pi) of miR-132 which might represent a response to
the well characterized TLR ligand activity of HSV 25, 26. Preliminary unpublished in vitro
experiments support this interpretation and our past observations that TLR-2 and TLR-9
knockout mice have diminished CV compared to wild type animals is in line with the
same interpretation18.
There are reasons, however, to consider that the direct binding effects by virus to
cells may not be the major stimulus for miR-132 production, particularly by vascular
endothelial cells. Accordingly, in the mouse model, virus replication is usually confined
to the corneal epithelium, but neovascularization occurs in the underlying stroma 2. Since
miRNAs exert regulatory effects only in cells that produce them, any effect of infection is
expected to be mediated indirectly via soluble molecules, such as cytokines and cell
breakdown products, generated during the course of infection. Our data, along with the
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published report of others 7, indicate that one agonist responsible for causing miR-132
production in vascular endothelial cells was VEGF-A. Evidence for this conclusion came
from in vivo observations that procedures that caused diminished VEGF-A production or
activity resulted in reduced levels of miR-132. For example, lowering VEGF-A levels by
a VEGF trap approach, or reducing the presence of some cell types such as neutrophils
that produce VEGF-A, resulted in diminished miR-132 levels. Perhaps more convincing
in favor of VEGF-A as responsible for miR-132 production, we showed that animals
treated with nanoparticles containing miR-132 antagomirs had reduced levels of
downstream signaling products of VEGF-A stimulation such as active Ras in the CD31
enriched cells (presumably blood vessel endothelial cells) than controls (figure 7).
An unsolved issue, however, is to explain the connection between the virus
infection and the VEGF-A production. Some have advocated that virus infected cells
themselves produce VEGF-A 27, but perhaps the more common circumstance is VEGF-A
production by several uninfected cell types in response to one or more agonists generated
as a consequence of the infection. These agonists include proinflammatory cytokines
such as IL-6 that we showed in previous study can cause inflammatory cell types to
produce VEGF-A

28

. An additional cytokine that could participate in causing VEGF-A

production is IL-17A. This cytokine is produced in the cornea after HSV infection mainly
by innate immune cells in initial stages and later on by CD4 Th17 T cells 29. In support of
IL-17A as involved in miR-132 production, we showed that levels of miR-132 produced
in WT mice after infection were higher than those in animals unable to respond to IL17A because they lacked the IL-17A receptor. Accordingly, IL-17RKO animals
displayed more miR-132 target, Ras-GAP in corneas after HSV infection.
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Our observation that miR-132 appears involved in orchestrating CV in an
infectious disease situation is a novel finding. It leads to the question as to the
therapeutic potential of targeting miRNAs as a means to control clinical
diseases. Progress on this topic has already been accomplished in some autoimmune and
neoplastic diseases

30

. Many studies focus on miR-155 that is involved in regulating

inflammatory pathways

31

. MiR-155 can be upregulated by exposure to several TLR

ligands and is over-expressed during some autoimmune diseases as well as a diverse
array of immune cell cancers 20. Of particular interest, knockout mice exist that lack miR155. Such mice are resistant to experimental autoimmune encephalomyelitis and collagen
induced arthritis and generate T cell responses that emphasize the Th2 pattern

32

. In

preliminary studies, we have shown that miR-155 may also be involved in the
pathogenesis of SK (unpublished results). In disease situations that involve changes in
one or more species of miRNAs, the issue will be to determine if modulating their
expression represents a

more

viable

approach

to

control

inflammatory

and

neoplastic diseases than other procedures. We are attempting to answer this question in
the SK system by comparing the miRNA antagomirs in nanoparticles approach with other
control procedures. So far there are no results to report. Whatever occurs, there is at least
one theoretical advantage of targeting miR-132 to control angiogenesis. Thus, antiangiogenic therapies that target single pathways such as VEGFR signaling often develop
resistance by upregulating alternative angiogenic growth factors 33. This problem can be
avoided using miR-132 since it removes an endogenous regulator (RasGAP) involved in
controlling responses to several angiogenic factors. On the other hand, since
miRNAs have multiple mRNA targets, a potential downside of the approach could be a
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crossfire effect that turns off some useful gene expression alongside that of the gene
being selected for silencing. The results of future studies will reveal when situations are
most appropriate for the use of miRNA for therapy.
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Figure 3.1. Expression of miR-132 after HSV infection. miRNA quantification in HSV
infected mice corneas: WT mice were infected with HSV-1 RE in one eye and 6 corneas
were collected and pooled for miRNA analysis by TaqMan QPCR. The expression levels
of miR-132 (A and miR-133a (B) at different time points post HSV infection in mice
corneas are shown (Pooled n=6 mice/group). One way ANOVA with Bonferroni’s post
hoc test was used to calculate the level of significance. P ( 0.01 (**), P ( 0.05 (*). Error
bars represent means ± SEM. The above experiments were repeated three times.
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Figure 3.2. IL-17A and VEGF-A upregulates miR-132 in corneas. WT mice were
infected with HSV-1 RE in one eye and 6 corneas were collected and pooled for miR-132
analysis by TaqMan QPCR. The 5 &g soluble VEGFR1/isotype treatment was begun on
day 2 p.i with additional doses on alternate days until day 6 and and miR-132
quantification was carried out at day 7 p.i (Pooled n=6 mice/group). In another set of
experiments, 5 &g soluble VEGFR1/isotype treatment was continued up to day 12 p.i and
corneas were analyzed for miR-132 expression at day 14 p.i (A) (Pooled n=6
mice/group). One way ANOVA with Bonferroni’s post hoc test was used to calculate the
level of significance. P ( 0.05 (*). Error bars represent means ± SEM. Neutrophil
depletion was carried out using anti Ly6G antibody as shown (B). The HSV infected
mice were treated with 200 &g of anti Ly6G/isotype antibody as shown and corneas were
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analyzed for VEGF-A levels by western blotting and for miR-132 expression by QPCR at
day 14 p.i (C&D) (Pooled n=6 mice/group). The level of significance was determined by
student’s t test (unpaired). P ( 0.01 (**), P ( 0.05 (*). WT and IL-17RKO mice were
infected with HSV-1 RE in one eye and 6 corneas were collected and pooled for RasGAP mRNA analysis at day 7 p.i (E) and miR-132 analysis by TaqMan QPCR at day 14
p.i. SK lesions (F), angiogenesis scores (G) and miR-132 expression (H) in HSV infected
IL-17RKO mice and WT mice at day 2, 7 and 14 p.i. are shown. (Pooled n=6
mice/group). Error bars represent means ± SEM. All experiments were repeated two
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Figure 3.3. Knockdown of miR-132 by antagomir-132 nanoparticles in eyes. (A) The
different doses of antagomir-132/scrambled sequences nanoparticle treatment was given to HSV
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infected mice as shown. The 2.5&g antagomir-132 treatment regimen resulted in peak miR-132
knockdown in the corneas (B) (Pooled n=6 mice/group). One way ANOVA with Bonferroni’s
post hoc test was used to calculate the level of significance. P ( 0.05 (*). These experiments
were repeated two times. WT mice were infected with HSV-1 RE in one eye and 6 corneas were
collected and pooled for analysis by QPCR or WB. The 2.5&g antagomir-132/scrambled
sequences were injected subconjunctively in HSV infected mice and the quantification of
RasGAP mRNA (C) from corneas isolated from different groups was carried out (Pooled n=6
mice/group). The level of significance was determined by student’s t test (unpaired). ***P (
0.001. These experiments were repeated two times. Error bars represent means ± SEM. Reducing
WB for Ras-GAP protein after treatment of HSV infected mice with 2.5&g antagomir132/scrambled sequences (D) (Pooled n=6 mice/group). The representative WB image of two
independent
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Figure 3.4. Reduction in angiogenic Ras activity after antagomir-132 treatment. WT mice
were infected with HSV-1 RE in one eye and 6 corneas were collected and pooled for analysis
by GTPase activation assays. (A) WT mice infected with HSV were treated with antagomir132/scrambled sequences nanoparticle as shown. The corneas collected at day 11 p.i. after
antagomir-132/scrambled sequences nanoparticle treatment were subjected to Ras (B&C) pull
down followed by reducing WB analysis for Ras of the respective groups (Pooled n=6
mice/group). The representative WB image is shown. The corneas collected at day 11 p.i. after
antagomir-132/scrambled sequences nanoparticle treatments were subjected to WB for the
detection of VEGF (D&E). The representative WB image is shown. These experiments were
repeated two times and densitometry analysis of the band strength is shown. One way ANOVA
with Bonferroni’s post hoc test was used to calculate the level of significance. P ( 0.001 (***).
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Error bars represent means ± SEM.
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Figure 3.5. Preventive administration of antagomir-132 diminishes angiogenesis and
SK. WT mice were infected with HSV-1 RE in one eye and 6 corneas were collected and
pooled for analysis by flow cytometry. (A) The 2.5&g antagomir-132/scrambled
sequences nanoparticle treatment was given to HSV infected mice as shown. The
antagomir-132 treatment regimen resulted in reduction in SK (B) and angiogenesis scores
(C) in HSV infected animals. The frequency and total cell number per cornea for
endothelial cells (CD31+ cells) (D & E), Gr1+, CD11b+ cells (presumably neutrophils) (F
& G) and CD4+ T cells (H & I) showed significant reduction in frequency and total cell
number per cornea after preventive antagomir-132 treatment (n=6-8 mice/group). The
level of significance was determined by student’s t test (unpaired). P ( 0.01 (**), P ( 0.05
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(*). Error bars represent means ± SEM. These experiments were repeated two times.
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Figure 3.6. Provision of antagomir-132 nanoparticles therapeutically diminishes
angiogenesis and SK. WT mice were infected with HSV-1 RE in one eye and 6 corneas
were collected and pooled for analysis by flow cytometry. The therapeutic 2.5&g
antagomir-132 nanoparticles treatment (A) resulted in reduction in SK (B) and
angiogenesis (C) scores in HSV infected animals. The frequency and total cell number
per cornea for endothelial cells (CD31+ cells) (D & E), Gr1+, CD11b+ cells (F & G) and
CD4+ T cells (H & I) showed significant reduction in total cell number per cornea after
therapeutic antagomir-132 nanoparticle treatment (n=12-18 mice/group). The level of
significance was determined by student’s t test (unpaired). P ( 0.01 (**), P ( 0.05 (*).
Error bars represent means ± SEM. These experiments were repeated two times.
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Figure 3.7. Illustration of antagomir-132 mediated inhibition of corneal
neovascularization (CV). Left panel describes outcome (CV) in HSV infected untreated
mice: HSV infection leads to upregulation of IL-17 in corneas. IL-17 (along with IL-6
and virus infected epithelial cells) increases VEGF (probably via increasing IL-1b, IL-6
and Cxcl1) levels in the eyes. VEGF thus acting through VEGFR2 receptors on the blood
vessel endothelial cells upregulates miR-132 expression via CREB transcription factor.
MiR-132 removes RasGAP (intrinsic inhibitor of Ras) leading to activation of Ras and
CV. Right panel describes modulation of CV by miR-132 silencing: Administration of
antagomir-132 nanoparticles leads to deposition of antagomir-132 cargo in blood vessel
endothelial cells resulting in silencing of miR-132. This leads to higher levels of
RasGAP, which thereby inhibits angiogenic Ras activity resulting in inhibition of CV.

"

%%&"

B

Isotype treated

Anti Ly6G treated

Corneas

A
0

HSV infection

Ly6G

Anti Ly6G (200 µg)/Isotype Ab
!
7

9

11

CD11b

12 days p.i.

Collection of corneas
and spleen

C

Isotype treated

Anti Ly6G treated

Spleen

Ly6G
CD11b
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corneas (B) and spleen (C) were analyzed for the presence of Ly6G+ CD11b+ cells.
Representative FACS plots from both groups are shown (n=5 mice/group).
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Figure 3.9. Antagomir-132 reduces CV and endothelial Ras activity in corneas after
HSV infection. WT mice were infected with HSV-1 RE in one eye and monitored for the
development of angiogenesis and SK. The therapeutic 2.5&g antagomir-132 nanoparticles
treatment (A) resulted in visible reduction in angiogenesis in antagomir-132 treated
animals (B) compared to mice treated with scrambled sequences (C). The HSV infected
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nanoparticle treated mice corneas. The purity up to the extent of 80-90% was achieved.
These CD31 enriched cells from respective groups were subjected to Ras (E) pull down
followed by reducing WB analysis for Ras of the respective groups (Pooled n=12
mice/group). The representative WB image of the two independent experiments is shown.
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Figure 3.10. Late antagomir-132 treatment slightly diminishes angiogenesis and SK.
WT mice were infected with HSV-1 RE in one eye. The 2.5&g antagomir-132/scrambled
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antagomir-132 treatment regimen resulted in slight reduction in SK (B) and angiogenesis
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Part IV
MicroRNA-155: Regulator of HSV-1 encephalitis but
promotes stromal keratitis
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Abstract
Herpes simplex virus (HSV) infection of humans can lead to life threatening herpes
simplex encephalitis (HSE) and sometimes blinding ocular lesion, stromal keratitis (SK).
Here, we show that mice with a deficiency of miR-155 are highly susceptible to HSE
with a majority of mice (75-80%) dyeing after ocular infection with HSV. Acyclovir
treatment (a day after virus reaches brain) reduced brain viral levels and protected miR155 knockout mice from HSE thus supporting the role for virus replication in brain as the
cause of encephalitis. Furthermore, HSV infected miR-155 deficient mice developed
compromised virus specific CD8 T cell responses. Additionally, miR-155KO survivors
developed attenuated HSK lesions in eyes. This phenotype was also evident after
knockdown of miR-155 in WT mice. miR-155 deficiency demonstrated diminished Th1
responses in corneas and lymphoid organs accompanied by a profound reduction in
inflammatory and angiogenic molecules in corneas. Furthermore, combinatorial blockade
of miR-132 and miR-155 led to potent reduction in ocular immunopathology. In
conclusion, we have discovered dual role for miR-155, a regulator of HSV encephalitis
but an enhancer of HSK.

Introduction
Herpes simplex virus infection generally causes mucocutaneous disease at oral and
genital surfaces. In some instances, HSV can induce lesions in the eyes leading to
blinding disease, stromal keratitis (SK)(Giménez, Suryawanshi et al. 2012) and due to its
neurotrophic nature HSV can also invade brain. HSV-1 is a major cause of encephalitis,
which is primarily controlled by IFNs, NK cells and CD8 T cells. MicroRNAs are small
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RNAs that regulate gene expression post transcriptionally(Lee, Feinbaum et al. 1993;
O'Connell, Rao et al. 2010). Whether miRNAs play any role in regulating herpes simplex
encephalitis

(HSE)

is

currently

unknown.
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,/6" &>%%J6" In this report, we show that miR-155 deficiency leads to increased
susceptibility of mice to HSV-1 encephalitis with majority of mice dyeing of
encephalitis. miR-155 null mice also demonstrated attenuated HSV specific CD8 T cell
responses in peripheral lymphoid organs. Additionally, miR-155 deficiency leads to
resistance to HSK. Thus, miR-155 protects brain from HSE but increases ocular
immunopathology after ocular HSV infection.

Methods
Mice: Female 6-8 wks old C57 BL/6 mice were purchased from Harlan Sprague Dawley
Inc. (Indianapolis, Indiana, USA). miR-155KO mice on a C57BL/6 background were
obtained from Jackson laboratories. The animals were housed in American Association of
Laboratory Animal Care-approved facilities at the University of Tennessee Knoxville.
All investigations followed guidelines of the institutional animal care and use committee.
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Virus: HSV-1 strain RE was propagated in Vero cell monolayers (ATCC no: CCL81).
Virus was grown in Vero cell monolayers (American Type Culture Collection, Manassas,
VA), titrated, and stored in aliquots at –80˚C until used.
Corneal HSV-1 infection and scoring: Corneal infections of mice were performed
under deep anesthesia. The mice were lightly scarified on their corneas with a 27-gauge
needle, and a 3 &l drop containing 104 PFU of HSV-1 RE was applied to one eye. These
mice were monitored for the development of encephalitis. The SK lesion severity and
angiogenesis in the eyes of mice were examined by slit-lamp biomicroscopy (Kowa
Company, Nagoya, Japan) as described previously(Rajasagi, Reddy et al. 2011).
Purification of astrocytes and microglia: Purification of astrocytes from < day 8
neonatal brains of WT and miR-155 deficient mice was carried out as per manufacturers
guidelines (Miltenyl Biotech). The purity to the extent of 90-95% was achieved in these
experiments and astrocytes were infected with HSV as described previously (Reinert,
Harder et al. 2012) and virus was quantified in the supernatant. For microglia isolation,
adult WT and miR-155 null mice brains were used. The microglial cells were stimulated
with TLR-2 ligand, TLR-4 ligand and HSV and inflammatory cytokines and chemokines
were measured.
Flow Cytometry: Single cell suspensions were prepared from cornea, cervical DLN, and
spleen of mice at different time points pi. The single cell suspensions obtained from
corneas, DLN, and spleen were stained for different cell surface molecules for FACS. All
steps were performed at 4°C. A total of 1)106 cells were first blocked with an
unconjugated anti-CD32/CD16 mAb for 30 min in FACS buffer. After washing with
FACS buffer, fluorochrome-labeled respective antibodies were added for 30 min on ice.
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Finally, the cells were washed three times and re-suspended in 1% para-formaldehyde.
The stained samples were acquired with a FACS Calibur (BD Biosciences) and the data
were analyzed using the FlowJo software. For corneas, total cell numbers were calculated
by acquiring the totality of the sample and taking in consideration of the total number of
corneas in the sample. To enumerate the number of IFN-" and IL-17 producing CD4+ T
cells or IFN-" and TNF producing CD8+ T, cells were stimulated under appropriate
conditions (PMA/IONO for CD4 T cells while gB or PMA/IONO for CD8 T cells) and
intracellular cytokine staining was performed.
Quantitative PCR (QPCR) and TaqMan QPCR: QPCR and Taqman miRNA QPCR
was performed as previously described. The primers used for QPCR were as follows: IL1b, IFN-g, TNF, CXCL1, CCL2, CXCL10, CXCR3, CXCR4, MMP-9, IL-6, IL-12, IL10, TGFb and beta actin. TaqMan MicroRNA Assay (Applied Biosystems, USA) for
miR-155 was used for quantification using a real-time PCR detection system and data
were normalized to the internal control small nucleolar RNA 202.
Viral plaque assay: Virus titers were measured in the brain, TG and eye swabs taken
from HSV infected mice using plaque assays as described previously by others(Mulik,
Xu et al. 2012).
Statistics: The statistical significance for SK lesion severity and angiogenesis between
two groups was determined using unpaired two-tailed student's t test. One way ANOVA
with Bonferroni’s post hoc test was used to calculate the level of significance for some
experiments. P ( 0.001 (***), P ( 0.01 (**), P ( 0.05 (*) were considered as significant
and results are expressed as mean ±SEM. For all statistical analysis, GraphPad Prism
software was used.
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Results and Discussion
miR-155 deficient mice die due to encephalitis after HSV-1 infection. miR-155 is an
intensely studied miRNA which plays critical role in inflammation(Bhattacharyya,
Balakathiresan et al. 2011), innate immunity and antibody production(Thai, Calado et al.
2007; O'Neill, Sheedy et al. 2011). No reports have yet evaluated the role of miRNAs in
regulation of HSE. We studied this using miR-155 deficient mouse on a C57B/6
background (miR-155KO). WT C57B/6 mice and miR-155KO animals were infected
ocularly with HSV-1 and monitored for ocular disease and neurological signs. All WT
mice were free from any neurological signs and resistant to HSE as observed
previously(Lundberg, Welander et al. 2007). Surprisingly, 75-80% of the miR-155
deficient mice developed encephalitis and died by day 9 post infection (figure 4.1A).
When virus levels in brain were measured in both groups at day 9 p.i. WT mice were
negative for HSV by plaque assay while all miR-155 deficient mice had very high titers
of virus in the brain (figure 4.1B). However, virus was cleared efficiently from corneas
and trigeminal ganglia in miR-155 null mice similar to results in WT animals (figure
4.2A-B). Overall, these results indicate that mice with a deficiency of miR-155 are highly
susceptible to HSE.
Virus replication in brain as a cause of death in miR-155 deficient mice. A series of
publications by Casanova and Zheng et al demonstrate that mutations in TLR-3-IFN axis
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are strongly associated with HSE thus supporting the role of uncontrolled virus
replication as a cause of HSE(Zhang, Jouanguy et al. 2007; Pérez de Diego, SanchoShimizu et al. 2010; Guo, Audry et al. 2011; Sancho-Shimizu, Pérez de Diego et al. 2011;
Herman, Ciancanelli et al. 2012; Lafaille, Pessach et al. 2012; Reinert, Harder et al.
2012). However, this issue remains debatable in mice with several reports showing
inflammation as a trigger of HSE and death(Kurt-Jones, Chan et al. 2004; Mansur, Kroon
et al. 2005; Wang, Bowen et al. 2012). We performed experiments in miR-155 deficient
mice to determine the exact cause of death (virus replication versus inflammation). HSV
after corneal infection enters brain by day 2-day 4 post infection(Shimeld, Efstathiou et
al. 2001). Similarly, we could detect virus in the brain of HSV infected miR-155 deficient
mice by day 3 post infection (figure 4.1C). Previous reports in mice show that even
though virus replication is inhibited in brain via administration of acyclovir, a day after
viral entry into brain, mice succumb to deadly encephalitis. This was explained by the
initiation of an inflammatory response by HSV in brain, which resulted in severe damage.
In those models, when the inflammatory responses were inhibited by neutrophil or
macrophage depletion studies, mice were protected from HSE. Surprisingly, when we
administered acyclovir to HSV infected miR-155 deficient mice (from day 4 p.i.), the
majority (80%) of mice were protected from encephalitis and this acyclovir treatment
significantly lowered brain viral titers in miR-155KO mice (figure 4.1D-E). In summary,
these results indicate that viral replication in the brain is the cause of encephalitis in miR155 null mice. Other groups have shown that TLR-2 mediated induction of inflammatory
cytokines by microglia is a major reason for death in HSE in mice. In our experiments,
miR-155 deficient microglia produced equivalent or in some cases even lesser amounts of
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inflammatory molecules, which also disfavors inflammation as a cause of encephalitis in
our case (figure 4.3A-L). Furthermore, experiments were performed to see whether
astrocytes from miR-155 null mice were more susceptible to HSV-1 as recently observed
by Paludan group with TLR-3 deficiency. Our results show that astrocytes isolated from
miR-155 deficient mice are slightly more susceptible to HSV-1 infection than their WT
counterparts but differences were not significant (data not shown). In additional
experiments, brain IFNb levels were evaluated in WT and miR-155KO animals at
different time points after infection. Interestingly, IFNb levels were slightly higher in
miR-155 null animals at all the time points tested (figure 4.2C) suggesting no global
defect in IFNb production in miR-155 deficient animals.
Impaired CD4 and CD8 T cell responses in miR-155 null mice after HSV-1
infection. miR-155 deficient mice demonstrate defects in the CD4 T cell and B cell
responses(Rodriguez, Vigorito et al. 2007; O'Connell, Kahn et al. 2010; Murugaiyan,
Beynon et al. 2011). Since CD4 and CD8 T cells are required to control HSV replication
in brain, experiments were carried out to measure the magnitude of T cell responses in
WT and miR-155 deficient mice infected with HSV. Recent report by the Paludan group
showed that even though TLR-3 null mice succumbed to HSV-2 mediated encephalitis,
those mice demonstrated equivalent CD4 and CD8 T cell responses to those of WT
mice(Reinert, Harder et al. 2012). We infected WT and miR-155KO mice and studied T
cell responses at day 9 p.i. In line with previous reports, miR-155 deficient mice
produced fewer CD4 T cells making IFNg in LN and spleen (figure 4.4A-D, G-J). The
lesser numbers of CD4 T cells producing IL-17A was also evident in LNs and spleens
taken from miR-155KO mice (data not shown). Also in accord with recent
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reports(Kohlhaas, Garden et al. 2009), miR-155 null mice revealed lesser Treg numbers
in LN and spleen than WT animals(Liston, Lu et al. 2008; Lu, Thai et al. 2009) (figure
4.4E-F, K-L). When CD8 T cell responses were analyzed, miR-155 deficient mice
generated lesser total CD8 T cells and virus specific (gB tetramer specific) CD8 T cell
responses (figure 4.5 and figure 4.6). When CD8 T cells from LN or spleen were
stimulated with gB (immunodominat epitope of HSV), miR-155 deficient animals
showed significantly fewer IFNg producing or IFNg and TNFa secreting CD8 T cells
compared to WT animals (figure 4.6A-L). This was also evident after non specific
stimulation of CD8 T cells (PMA/Ionomycin). As in this case, miR-155 deficient mice
produced lesser IFNg or IFNg and TNFa secreting CD8 T cells in LN and spleen (figure
4.5A-L). In conclusion, these results support viral replication as the cause of encephalitis
in miR-155 deficient mice and such defect in viral clearance could be due to
compromised CD4 and CD8 T cell responses in peripheral lymphoid organs.
miR-155 deficiency leads to attenuated SK lesions and demonstrate diminished Th1
responses.

Mice

infected

ocularly

with

HSV

develop

ocular

immunopathology(Niemialtowski and Rouse 1992). We did these experiments to see
whether miR-155 deficient mice differ in susceptibility to SK. Recent reports show that
miR-155KO mice are resistant to multiple sclerosis and rheumatoid arthritis
models(O'Connell, Kahn et al. 2010; Blüml, Bonelli et al. 2011). All WT mice infected
with HSV developed SK but miR-155 KO survivors from encephalitis were relatively
resistant to SK and revealed significantly lower SK lesion scores and the extent of
angiogenesis (figure 4.7A-D). Recently, Baltimore group demonstrated that miR-155 KO
animals generate significantly lower pathogenic Th1 and Th-17 cells(O'Connell, Kahn et
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al. 2010). In line with these reports, HSV infected miR-155 deficient mice produced
fewer Th1 cells in LN, spleen and corneas (figure 4.8A-I). In another set of experiments,
we locally knocked down miR-155 using antagomir-155 nanoparticles in eyes of WT
mice. This treatment modality did not increase susceptibility of those mice to encephalitis
after HSV infection but resulted in significant reduction in ocular immunopathology, led
to a potent reduction in inflammatory and angiogenic molecules in eyes (figure 4.7EJ)(Bhattacharyya, Balakathiresan et al. 2011). Interestingly, silencing of both miR-155
and miR-132 (angiogenic)(Zheng, Schwarz et al. 2001; Anand, Majeti et al. 2010; Mulik,
Xu et al. 2012) led to potent reduction in severity of SK and an extent of angiogenesis
(figure 4.7) meaning combinatorial blockade(Kim, Tang et al. 2004) of both miRNAs
could have translational potential to treat SK.
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Figure 4.1. miR-155 null mice are very susceptible to HSV-1 encephalitis. A) WT and
miR-155 deficient mice were ocularly infected with HSV and monitored for the
development of encephalitis and death. B) Brian viral titers in WT and miR-155 null
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Figure 4.7. miR-155 deficiency makes mice resistant to SK. A-D) WT and miR-155
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Conclusions and future perspectives

Herpes simplex virus infection generally leads to lesions on oral surface. In rare
instances, virus can induce damage of the eyes (herpetic stromal keratitis) or brain
(herpes simplex encephalitis). HSK remains the leading cause of infectious blindness in
the

western

world

and

the

current

therapies

are

unsatisfactory.

Corneal

neovascularization is a critical step in the pathogenesis of HSK and studies using mouse
models demonstrate that inhibition of corneal blood vessel development may halt disease
progression. Our past studies have firmly established an essential role of VEGF in CV
and therapies that remove the source of VEGF, or inhibit VEGF activity or VEGF
signaling have shown promise in treating HSK in mouse models.
Our first approach to inhibit CV was augmentation of regulatory pathways. We
chose Slit2-Robo4 signaling as it was shown to play a modulatory role in cancer models.
After virus infection, we found upregulation of Robo4 but Slit2 expression was
diminished. Additionally, our results demonstrate that potentiation of Robo4 signaling by
administration of Slit2 significantly reduced CV. We plan to extend our observations and
look in depth at molecular mechanisms to determine why Slit2 induction is inhibited in
eyes after HSV infection. In this aspect, we will look at the expression of several
microRNAs targeting Slit2 in eyes. We will also perform experiments in vitro in a
corneal cell line and in vivo in mice by addition of certain cytokines or using cytokineneutralizing antibodies to evaluate Slit2 expression. We intend to administer Slit2 in
nanoparticles to HSV infected mice. Additionally, we plan to use Arf6 or Rac1 inhibitor
(which will mimic Slit2-Robo4 signaling) and will study the expression of HSK after
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such treatment modalities. Optimistically, potentiation of Slit2-Robo4 signaling may help
to reduce human SK.
Our other attempts to reduce HSK involved manipulation of microRNAs, which
have been recently shown to play a role in several human diseases. miRNAs are post
transcriptional regulators of gene expression and they do it so by promoting degradation
of mRNA or inhibition of protein translation. miRNA blockade offers new opportunities
to halt the progression of human diseases. We focused on miR-132 and miR-155 since
these miRNAs play a pivotal role in angiogenesis and inflammation respectively.
miR-132 is one of the highly conserved miRNA and its function depends on the
context where it is expressed. Accordingly, miR-132 induced neuronal differentiation in
brain, performed anti-inflammatory action at neural immune interface, and promoted
IFNs in KSHV infected lymphatic endothelial cells while it induced an angiogenic switch
in cancer. Our results show that miR-132 expression is upregulated in corneas and it
enhanced VEGF signaling during HSK. Inhibition of miR-132 significantly reduced CV.
We plan to perform future experiments in miR-132 deficient mice, which we believe
could be relatively resistant to CV. We intend to investigate miR-132 targets in depth in
collaboration using various 3’UTR gene mutated plasmids. We also plan to investigate
development of lymphatic vessels in corneas of miR-132 deficient mice after HSV
infection. Additionally, we will block the activity of other angiogenic or tissue damaging
molecules in miR-132 deficient mice and will look at the expression of HSK.
Furthermore, we will also attempt to design slow drug release antagomir-132
nanoparticles that could be given topically to the eyes. We hope that miR-132 blockade
approaches will someday be useful for human HSK therapy.
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miR-155 is one of the intensely studied miRNA and it is required for normal
immune function. Recent reports suggest that miR-155 is tightly linked with the
inflammatory processes and is needed for the generation of pathogenic Th1 and Th17
cells. Consequently, mice deficient in miR-155 are resistant to some inflammatory and
autoimmune diseases such as EAE and RA. We observed induction of miR-155 in eyes
after herpes infection. Surprisingly, after infection with HSV, 80% miR-155KO mice
died by encephalitis due to uncontrolled virus replication and those miR-155 deficient
mice demonstrated a defect in CD8 T cells as well as other immune cells. We also
studied miR-155KO survivors and those animals were relatively resistant to HSK. This
phenotype was also evident after local knockdown of miR-155 in eyes. Finally, when
miR-132 and miR-155 were inhibited together, this treatment modality potently reduced
CV and HSK lesion severity. Future experiments will be performed to investigate the
CD8 T cell defect in miR-155 KO mice as well as study of the miR-155 targets after local
miR-155 silencing.
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